SEARCH

Search Details

SAWADA Ryoko
University Hospital / Orthopedic Surgery
Assistant Professor

Researcher basic information

■ Research Areas
  • Life sciences / Orthopedics

Research activity information

■ Paper
  • Tomohiro Miyamoto, Naomasa Fukase, Teruya Kawamoto, Shuichi Fujiwara, Hitomi Hara, Ryoko Sawada, Yuta Nakamatsu, Yutaka Mifune, Kenichiro Kakutani, Yuichi Hoshino, Shinya Hayashi, Tomoyuki Matsumoto, Takehiko Matsushita, Michiyo Koyanagi-Aoi, Takashi Aoi, Toshiyuki Takemori, Shunsuke Yahiro, Ryosuke Kuroda, Toshihiro Akisue
    Cancer stem cells (CSCs) have been implicated as critical mediators in the progression, chemoresistance and metastatic capabilities of diverse malignancies, including osteosarcoma (OS). The authors have succeeded in generating CSC‑like cells (MG‑OKS) from the OS cell line MG‑63 by transducing defined factors. A significant increase in small proline‑rich protein 1A (SPRR1A) expression, a cross‑linked envelope protein in keratinocytes, was observed in MG‑OKS cells. Therefore, SPRR1A could be involved in tumor initiation, growth and poor OS progression. However, its specific role in OS remains unclear. The present study aimed to evaluate the role of SPRR1A in OS both in vitro and in vivo using MG‑OKS cells. Three experimental groups were established: MG‑OKS cells transfected with SPRR1A small interfering (si)RNA (siMG‑OKS), untransfected MG‑OKS cells and MG‑OKS cells transfected with scrambled siRNA (scMG‑OKS) as controls. SPRR1A expression, morphological changes, cell proliferation and migration were assessed in these groups. RNA sequencing was performed to examine the genetic changes caused by SPRR1A suppression. To evaluate tumorigenicity in vivo, cells from each group were subcutaneously transplanted into the backs of nude mice. Tumor volume and Ki‑67 expression were assessed and compared among the three groups at four weeks post‑transplantation. The siMG‑OKS group exhibited altered cell morphology, reduced cell proliferation and decreased migratory abilities in vitro. RNA sequencing revealed suppression of genes involved in cell adhesion in the siMG‑OKS group. Furthermore, the in vivo tumorigenicity of siMG‑OKS was lower than that of the other two experimental groups. These findings suggest that SPRR1A is one of the key cell adhesion‑related molecules involved in OS progression, potentially serving as a therapeutic target for this refractory tumor. However, further research is needed to fully elucidate the mechanisms by which SPRR1A influences OS pathogenesis and to explore its clinical potential.
    Feb. 2025, Oncology reports, 53(2) (2), English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • がんロコモ対策の現状と課題 四肢骨転移に対する治療の現状と課題
    原 仁美, 深瀬 直政, 澤田 良子, 藤原 周一, 秋末 敏宏, 黒田 良祐
    (一社)中部日本整形外科災害外科学会, Oct. 2024, 中部日本整形外科災害外科学会雑誌, 68(秋季学会) (秋季学会), 68 - 68, Japanese

  • 整形外科における女性医師キャリア形成の現状と課題 自身のキャリア形成の現状と課題 1度手術を手放した私が再び手術を学ぶチャンスをつかむまで
    澤田 良子, 藤原 周一, 深瀬 直政, 原 仁美, 秋末 敏宏, 黒田 良祐
    (一社)中部日本整形外科災害外科学会, Oct. 2024, 中部日本整形外科災害外科学会雑誌, 68(秋季学会) (秋季学会), 92 - 92, Japanese

  • 肘部管症候群を合併した右肘滑膜軟骨腫症の一例
    藤原 周一, 原 仁美, 深瀬 直政, 澤田 良子, 秋末 敏宏, 黒田 良祐
    (一社)中部日本整形外科災害外科学会, Oct. 2024, 中部日本整形外科災害外科学会雑誌, 68(秋季学会) (秋季学会), 269 - 269, Japanese

  • 中松 裕太, 深瀬 直政, 原 仁美, 澤田 良子, 藤原 周一, 宮本 智弘, 八尋 俊輔, 青井 三千代, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2024, 日本整形外科学会雑誌, 98(8) (8), S1964 - S1964, Japanese

  • 宮本 智弘, 藤原 周一, 原 仁美, 深瀬 直政, 澤田 良子, 中松 裕太, 青井 貴之, 小柳 三千代, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2024, 日本整形外科学会雑誌, 98(8) (8), S1967 - S1967, Japanese

  • Toshiyuki Takemori, Hitomi Hara, Teruya Kawamoto, Naomasa Fukase, Ryoko Sawada, Shuichi Fujiwara, Ikuo Fujita, Takuya Fujimoto, Masayuki Morishita, Shunsuke Yahiro, Tomohiro Miyamoto, Masanori Saito, Jun Sugaya, Katsuhiro Hayashi, Hiroyuki Kawashima, Tomoaki Torigoe, Tomoki Nakamura, Hiroya Kondo, Toru Wakamatsu, Munenori Watanuki, Munehisa Kito, Satoshi Tsukushi, Akihito Nagano, Hidetatsu Outani, Shunichi Toki, Shunji Nishimura, Hiroshi Kobayashi, Itsuo Watanabe, Yusuke Demizu, Ryohei Sasaki, Takumi Fukumoto, Tomoyuki Matsumoto, Ryosuke Kuorda, Toshihiro Akisue
    BACKGROUND: Few studies have compared the clinical outcomes of patients with pelvic bone sarcomas treated surgically and those treated with particle beam therapy. This is a multicenter retrospective cohort study which compared the clinical outcomes of patients with pelvic bone sarcoma who underwent surgical treatment and particle beam therapy in Japan. METHODS: A total of 116 patients with pelvic bone sarcoma treated at 19 specialized sarcoma centers in Japan were included in this study. Fifty-seven patients underwent surgery (surgery group), and 59 patients underwent particle beam therapy (particle beam group; carbon-ion radiotherapy: 55 patients, proton: four patients). RESULTS: The median age at primary tumor diagnosis was 52 years in the surgery group and 66 years in the particle beam group (P < 0.001), and the median tumor size was 9 cm in the surgery group and 8 cm in the particle beam group (P = 0.091). Overall survival (OS), local control (LC), and metastasis-free survival (MFS) rates were evaluated using the Kaplan-Meier method and compared among 116 patients with bone sarcoma (surgery group, 57 patients; particle beam group, 59 patients). After propensity score matching, the 3-year OS, LC, and MFS rates were 82.9% (95% confidence interval [CI], 60.5-93.2%), 66.0% (95% CI, 43.3-81.3%), and 78.4% (95% CI, 55.5-90.5%), respectively, in the surgery group and 64.9% (95% CI, 41.7-80.8%), 86.4% (95% CI, 63.3-95.4%), and 62.6% (95% CI, 38.5-79.4%), respectively, in the particle beam group. In chordoma patients, only surgery was significantly correlated with worse LC in the univariate analysis. CONCLUSIONS: The groups had no significant differences in the OS, LC, and MFS rates. Among the patients with chordomas, the 3-year LC rate in the particle beam group was significantly higher than in the surgery group.
    Jul. 2024, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, English, Domestic magazine
    Scientific journal

  • Ryoko Sawada, Yusuke Shinoda, Takahiro Ohki, Yuki Ishibashi, Hiroshi Kobayashi, Sakae Tanaka, Nobuhiko Haga
    BACKGROUND: Working while receiving cancer treatment is challenging for patients, with considerable impact on their quality of life (QOL). However, there have been no reports on the factors that prevent employment in patients with bone metastases. This study aimed to investigate the employment status and factors impacting the continued employment of patients with bone metastases. METHODS: We analyzed clinical data from new patients consulting The University of Tokyo Hospital team for bone metastasis treatment between June 2015 and September 2017. Patients who were working at the time of cancer diagnosis (n = 124) completed four QOL questionnaires. Factors associated with work sustainability were identified via univariate analysis and a chi-squared test. Multivariate logistic regression analysis was used for significant variables. Relationships between employment and QOL scales were investigated using the Wilcoxon rank-sum test, with P < .05 considered as statistically significant. RESULTS: Among the 124 patients, only 45 (36.3%) were still working when the questionnaire was administered. Multivariate analysis revealed temporary employment, lytic or mixed bone metastases, and lower limb or acetabular metastasis, as significant factors hindering work sustainability. The QOL scores were high in the continued employment group. However, the relationship between employment status and pain remains unclear. CONCLUSIONS: Lytic or mixed bone metastases and the lower limb and acetabular metastasis were significantly associated with employment resignation. Mobility difficulties may prevent patients with bone metastases from sustaining employment. Collaboration between rehabilitation professionals, oncologists, and workplaces is imperative to address this problem.
    Jun. 2024, Japanese journal of clinical oncology, English, International magazine
    Scientific journal

  • 深瀬 直政, 原 仁美, 澤田 良子, 藤原 周一, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2024, 日本整形外科学会雑誌, 98(6) (6), S1506 - S1506, Japanese

  • 原 仁美, 深瀬 直政, 澤田 良子, 藤原 周一, 宮本 智弘, 中松 裕太, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2024, 日本整形外科学会雑誌, 98(6) (6), S1599 - S1599, Japanese

  • 藤原 周一, 出水 祐介, 原 仁美, 深瀬 直政, 澤田 良子, 宮本 智弘, 中松 裕太, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2024, 日本整形外科学会雑誌, 98(6) (6), S1674 - S1674, Japanese

  • 中松 裕太, 深瀬 直政, 原 仁美, 澤田 良子, 藤原 周一, 宮本 智弘, 八尋 俊輔, 青井 三千代, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2024, 日本整形外科学会雑誌, 98(6) (6), S1527 - S1527, Japanese

  • 宮本 智弘, 藤原 周一, 原 仁美, 深瀬 直政, 澤田 良子, 中松 裕太, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2024, 日本整形外科学会雑誌, 98(6) (6), S1528 - S1528, Japanese

  • 小児脛骨に発症したBCG骨髄炎の1例
    中松 裕太, 原 仁美, 澤田 良子, 山本 暢之, 秋末 敏宏, 黒田 良祐
    (一社)中部日本整形外科災害外科学会, Apr. 2024, 中部日本整形外科災害外科学会雑誌, 67(春季学会) (春季学会), 175 - 175, Japanese

  • 原 仁美, 深瀬 直政, 澤田 良子, 藤原 周一, 宮本 智弘, 中松 裕太, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Mar. 2024, 日本整形外科学会雑誌, 98(2) (2), S530 - S530, Japanese

  • Ryoko Sawada, Yusuke Shinoda, Takahiro Ohki, Yuki Ishibashi, Hiroshi Kobayashi, Yoshitaka Matsubayashi, Sakae Tanaka, Nobuhiko Haga
    BACKGROUND: Even terminal cancer patients desire to walk to the toilet by themselves until the very last day. This study aimed to describe the walking ability of patients with spinal metastases at the end-of-life stage and identify the factors affecting this ability. METHODS: Among 527 patients who first visited our multidisciplinary team for bone metastasis between 2013 and 2016, 56 patients who had spinal metastases with a Spinal Instability Neoplastic Score ≥7 and died during follow-up were included. We collected general clinical data, performance status, Frankel classification, epidural spinal cord compression scale and Spinal Instability Neoplastic Score at the first consultation. Patients' last day of walking and date of death were also examined. Univariate analyses (chi-squared tests) were performed to identify the factors that impacted walking ability 30 and 14 days before patients' death. RESULTS: A total of 56 patients were extracted, and 57.1% (32/56) and 32.7% (16/49) of patients were ambulatory 30 and 14 days before death, respectively. Their performance status (P = 0.0007), Frankel grade (P = 0.012) and epidural spinal cord compression grade (P = 0.006) at the first examination, and administration of bone modifying agents during follow-up period (P = 0.029) were significantly related to walking ability 30 days before death. Among ambulatory patients 30 days before death, those with Spinal Instability Neoplastic Score ≥10 (P = 0.005), especially with high scores of collapse (P = 0.002) and alignment (P = 0.002), were less likely to walk 14 days before death. The walking period in the last month of their life was significantly longer in patients with total Spinal Instability Neoplastic Score 7-9 (P = 0.009) and in patients without collapse (P = 0.040) by the Wilcoxon test. CONCLUSION: The progression of spinal metastasis, especially neurological deficit, at the initial consultation were associated with walking ability 30 days before death, and spinal stability might be crucial for preserving walking ability during the last month. Early diagnosis and implementation of appropriate bone management might be important for the end-of-life walking ability.
    Jan. 2024, Japanese journal of clinical oncology, 54(1) (1), 81 - 88, English, International magazine
    Scientific journal

  • 左第2肋骨に生じた骨軟骨腫を胸腔鏡補助下に摘出した一例
    和田 悠花, 原 仁美, 澤田 良子, 田中 雄悟, 黒田 良祐, 秋末 敏宏
    (一社)中部日本整形外科災害外科学会, Oct. 2023, 中部日本整形外科災害外科学会雑誌, 66(秋季学会) (秋季学会), 318 - 318, Japanese

  • 藤原 周一, 河本 旭哉, 原 仁美, 深瀬 直政, 澤田 良子, 八尋 俊輔, 宮本 智弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1382 - S1382, Japanese

  • 宮本 智弘, 藤原 周一, 河本 旭哉, 原 仁美, 深瀬 直政, 澤田 良子, 八尋 俊輔, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1435 - S1435, Japanese

  • 深瀬 直政, 藤原 周一, 竹森 俊幸, 出水 祐介, 沖本 智昭, 澤田 良子, 原 仁美, 河本 旭哉, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1439 - S1439, Japanese

  • 竹森 俊幸, 河本 旭哉, 藤田 郁夫, 藤本 卓也, 原 仁美, 深瀬 直政, 澤田 良子, 藤原 周一, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1440 - S1440, Japanese

  • Hitomi Hara, Teruya Kawamoto, Naomasa Fukase, Ryoko Sawada, Shuichi Fujiwara, Shunsuke Yahiro, Tomohiro Miyamoto, Tomoaki Terakawa, Yutaka Mifune, Yuichi Hoshino, Kenichiro Kakutani, Tomoyuki Matsumoto, Takehiko Matsushita, Takahiro Niikura, Ryosuke Kuroda, Toshihiro Akisue
    INTRODUCTION: The introduction of tyrosine kinase inhibitors has revolutionized treatment strategies for metastatic renal cell carcinoma (RCC) and has improved survival rates. The number of patients with bone metastases from RCC requiring surgery will increase as survival rates improve. However, there is insufficient evidence to standardize the treatment of bone metastases after the introduction of targeted therapy for metastatic RCC. We aimed to determine the outcomes of palliative surgical treatment of bone metastases in the extremities of patients with metastatic RCC. MATERIALS AND METHODS: We retrospectively reviewed 26 lesions from 17 patients who underwent surgery for extremity and acetabular bone metastases and were treated with targeted therapies for advanced RCC between 2008 and 2020. The median follow-up duration was 19 months (range, 4-76). We assessed the patients' activities of daily living, quality of life, and pain and analyzed their postoperative values relative to preoperative values. Postoperative overall survival (OS), local progression-free survival (LPFS), and the factors affecting them were evaluated using the Kaplan-Meier method and log-rank test. RESULTS: The 5-year OS and LPFS rates were 39.5% and 65.6%, respectively. The factors affecting OS were sex, Katagiri score, visceral metastases, and preoperative targeted therapy, while the factors affecting LPFS were pathologic fractures and surgical technique. CONCLUSION: In this study, the postoperative outcomes of palliative surgery for bone metastases from metastatic RCC were good. We suggest that systemic treatment should be prioritized over local control for advanced bone metastasis in RCC and surgery before pathological fracture should be performed for local control.
    May 2023, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 49(5) (5), 928 - 933, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Shunsuke Yahiro, Teruya Kawamoto, Shuichi Fujiwara, Hitomi Hara, Naomasa Fukase, Ryoko Sawada, Toshiyuki Takemori, Tomohiro Miyamoto, Yutaka Mifune, Kenichiro Kakutani, Yuichi Hoshino, Shinya Hayashi, Tomoyuki Matsumoto, Takehiko Matsushita, Michiyo Koyanagi-Aoi, Takashi Aoi, Ryosuke Kuroda, Toshihiro Akisue
    Ewing sarcoma (ES) is an aggressive primary malignant bone tumor that predominantly affects children and young adults. Multimodal treatment approaches have markedly improved the survival of patients with localized ES. However, local recurrence and distant metastasis following curative therapies remain a main concern for patients with ES. Recent studies have suggested that slow‑cycling cells (SCCs) are associated with tumor progression, local recurrence and distant metastasis in various types of cancers. According to the results of these studies, it was hypothesized that SCCs may play a critical role in tumor progression, chemoresistance and local/distal recurrence in patients with ES. The present study applied a label‑retaining system using carboxyfluorescein diacetate succinimidyl ester (CFSE) to identify and isolate SCCs in ES cell lines. In addition, the properties of SCCs, including sphere formation ability, cell cycle distribution and chemoresistance, in comparison with non‑SCCs were investigated. RNA sequencing also revealed several upregulated genes in SCCs as compared with non‑SCCs; the identified genes not only inhibited cell cycle progression, but also promoted the malignant properties of SCCs. On the whole, the present study successfully identified SCCs in ES cells through a label‑retaining system using CFSE. Moreover, to the best of our knowledge, the present study is the first to describe the characteristic properties of SCCs in ES. The findings of this study, if confirmed, may prove to be useful in elucidating the underlying molecular mechanisms and identifying effective therapeutic targets for ES.
    Nov. 2022, International journal of oncology, 61(5) (5), English, International magazine
    Scientific journal

  • Hiroshi Kobayashi, Tomotake Okuma, Koichi Okajima, Yuki Ishibashi, Liuzhe Zhang, Toshihide Hirai, Takahiro Ohki, Masachika Ikegami, Ryoko Sawada, Yusuke Shinoda, Toru Akiyama, Takahiro Goto, Sakae Tanaka
    BACKGROUND: Eribulin is a tubulin and microtubule-targeting drug that has clinical benefit in overall survival (OS) for patients with advanced soft tissue sarcoma. Eribulin's efficacy has been confirmed in several clinical trials, although no clinically useful biomarkers have been identified. We therefore sought to clarify the predictive factor of eribulin treatment, while focusing on systemic inflammation and immune response values. METHODS: This study included 33 advanced STS patients treated with eribulin between March 2016 and September 2019. We evaluated the associations of clinical factors influencing the efficacy of eribulin treatment and systemic inflammatory and immune response, including the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the lymphocyte-to-monocyte ratio (LMR), the systemic inflammation response index (SIRI), and the prognostic nutrition index (PNI), with progression-free survival (PFS) and OS using the Kaplan-Meier method and log-rank test. RESULTS: NLR, LMR, PLR, SIRI, and PNI were unassociated with PFS. Compared with patients with SIRI <1.5, those with an SIRI ≥1.5 had a significantly shorter OS [median OS 15 months (95% confidence interval [CI] 8-not reached) vs. 7 months (95% CI 3-14), P = 0.04]. Moreover, the PFS tended to be shorter for patients with SIRI ≥1.5 who received chemotherapy after eribulin treatment than in those with SIRI >1.5 [median PFS 92.5 days (95% CI 27-204) vs. 133 days (95% CI 36-507), P = 0.08]. CONCLUSIONS: High SIRI values may predict poorer overall survival and the efficacy of subsequent drugs after eribulin treatment among patients with advanced soft tissue sarcoma.
    Jan. 2022, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 27(1) (1), 222 - 228, English, Domestic magazine
    Scientific journal

  • Ryoko Sawada, Hayato Yamana, Yusuke Shinoda, Yusuke Tsuda, Hiroki Matsui, Kiyohide Fushimi, Hiroshi Kobayashi, Yoshitaka Matsubayashi, Hideo Yasunaga, Sakae Tanaka, Nobuhiko Haga
    BACKGROUND: Surgical procedure for symptomatic spinal metastasis is expected to improve the quality of life. Factors related to short-term perioperative mortality after surgery for spinal metastasis may be different from those related to long-term mortality, which have classically been used to determine the indication for surgery. The purposes of this study were to evaluate factors related to the 30-day mortality after surgery for spinal metastasis and create an integer risk scoring system. METHODS: Using the Diagnosis Procedure Combination database from 2010 to 2016, we extracted data of patients who underwent surgical procedure for spinal metastasis. Multivariable logistic regression analysis was performed to clarify the association between patient backgrounds and the 30-day postoperative mortality. We created a risk scoring system using regression coefficients to estimate the 30-day mortality for each patient. RESULTS: Among 3524 patients, the 30-day mortality was 2.6%. Factors associated with a higher 30-day mortality were male sex (odds ratio, 2.50 [95% confidence interval, 1.45-4.31]), emergency admission (1.80 [1.11-2.92]), rapid growth tumors (3.83 [2.49-5.90]), and non-skeletal metastasis (2.27 [1.42-3.64]). In patients with the maximum risk score of five, the 30-day mortality was 16.2%. CONCLUSIONS: Factors related to the 30-day mortality were male sex, emergency admission, rapid growth tumors, and non-skeletal metastasis. These findings provide spine surgeons and patients knowledge of the potential risk of short-term perioperative mortality and allow them to consider the risk of surgery.
    Jul. 2021, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 26(4) (4), 666 - 671, English, Domestic magazine
    Scientific journal

  • Yuki Ishibashi, Hiroshi Kobayashi, Ryoko Sawada, Tomotake Okuma, Koichi Okajima, Liuzhe Zhang, Toshihide Hirai, Takahiro Ohki, Masachika Ikegami, Yusuke Shinoda, Toru Akiyama, Takahiro Goto, Sakae Tanaka
    BACKGROUND: Soft tissue metastasis is rarer than bone metastasis. Patients with soft tissue metastasis generally have a dismal prognosis. The treatment for metastatic lesions is sometimes difficult, because the prognostic factors of patients with soft tissue metastasis remain unelucidated. Therefore, this study aimed to identify these prognostic factors. METHODS: Thirty-one patients with soft tissue metastasis were included in the study. We evaluated associations of overall survival with clinical parameters and inflammatory markers using Kaplan-Meier curves and Cox proportional hazards models. RESULTS: Twelve patients received surgery for soft tissue metastasis, while radiation therapy was performed in six cases. The median overall survival after the detection of soft tissue metastasis was 11 months. Univariate analysis revealed that detection of soft tissue metastasis after the multidisciplinary treatment (P = 0.01); solitary metastasis (P = 0.0003); and pretreatment C-reactive protein (CRP) level < 0.4 mg/dL (P < 0.0001), white blood cell count < 8500 × 103/μL (P = 0.0003), and neutrophil-to-lymphocyte ratio < 5 (P = 0.02) were significant good prognostic factors. Multivariate analysis revealed that a CRP value < 0.4 mg/dL (P = 0.07) and solitary metastasis (P = 0.09) were possible significant predictors of survival. Furthermore, in case of CRP levels <0.4 mg/dL and metastatic tumor resection, patients had a good prognosis; however, when the CRP levels increased to 0.4 mg/dL and above, patients had a poor prognosis, irrespective of tumor resection. CONCLUSIONS: CRP is potentially useful for determining the indication of radical metastasectomy in soft tissue metastasis.
    May 2021, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 26(3) (3), 478 - 482, English, Domestic magazine
    Scientific journal

  • Yusuke Shinoda, Ryoko Sawada, Yuki Ishibashi, Toru Akiyama, Liuzhe Zhang, Toshihide Hirai, Hiroyuki Oka, Takahiro Ohki, Masachika Ikegami, Koichi Okajima, Tomotake Okuma, Hiroshi Kobayashi, Takahiro Goto, Nobuhiko Haga, Sakae Tanaka
    Lower limb pathological fractures caused by bone metastases can severely impair activities of daily living, so recognizing fracture risk is essential. Medial cortical involvement (MCI) in the proximal femur has been demonstrated to affect bone strength in biomechanical studies, but it has not been investigated in real patients. Between 2012 and 2019, 161 bone metastases with computed tomography (CT) images were retrospectively examined. Twenty-nine fractures were observed including 14 metastases with pathological fractures at the first examination, and prophylactic surgery was performed for 50 metastases. We extracted clinicopathological data using CT images, including patient's background, MCI in the proximal femur, site, size, circumferential cortical involvement (CCI), pain, and nature of metastasis. Cox proportional hazard regression analyses were performed, and we created integer scores for predicting fractures. We revealed that MCI, CCI, lytic dominant lesion, and pain were significant factors by univariate analyses. By multivariable analysis, MCI and each 25% CCI were significant and integer score 1 was assigned based on hazard ratio. The full score was four points, with MCI in the proximal femur (one point) and ≥ 75% CCI (three points). With integer score two, sensitivity was 88.9% and specificity was 81.2% for predicting fracture within 60 days. In conclusion, MCI and CCI examined by CT images were the risk factors for pathological fracture. CCI ≥ 50% is a widely known risk factor, but in addition, it may be better to consider surgery if MCI in the proximal femur is observed in metastasis with 25-50% CCI.
    Oct. 2020, Clinical & experimental metastasis, 37(5) (5), 607 - 616, English, International magazine
    Scientific journal

  • Shoichiro Tani, Yutaka Morizaki, Kosuke Uehara, Ryoko Sawada, Hiroshi Kobayashi, Yusuke Shinoda, Hirotaka Kawano, Sakae Tanaka
    OBJECTIVE: In contrast to acrometastasis, defined as bone metastasis to the hand or foot, the frequency and prognosis of bone metastasis of other limb segments remain unclear. To compare prognosis according to sites of bone metastasis, we defined two new terms in this study: 'mesometastasis' and 'rhizometastasis' as bone metastasis of 'forearm or lower leg' and 'arm or thigh', respectively. METHODS: A total of 539 patients who were registered to the bone metastasis database of The University of Tokyo Hospital from April 2012 to May 2016 were retrospectively surveyed. All patients who were diagnosed to have bone metastases in our hospital are registered to the database. Patients were categorized into four groups according to the most distal site of bone metastases: 'acrometastasis', 'mesometastasis', 'rhizometastasis' and 'body trunk metastasis'. RESULTS: The frequency of rhizometastasis (22.5%) or body trunk metastasis (73.1%) was significantly higher than that of acrometastasis (2.0%) or mesometastasis (2.4%). The median survival time after diagnosis of bone metastases for each group was as follows: 6.5 months in acrometastasis, 4.0 months in mesometastasis, 16 months in rhizometastasis, 17 months in body trunk metastasis and 16 months overall. In survival curve, there was a statistically significant difference between mesometastasis and body trunk metastasis. CONCLUSIONS: Our findings suggest that 'mesometastasis' could be another poor prognostic factor in cancer patients and that patients with mesometastasis should receive appropriate treatments according to their expected prognosis.
    Sep. 2020, Japanese journal of clinical oncology, 50(10) (10), 1226 - 1226, English, International magazine
    Scientific journal

  • Nobuhiko Haga, Yasuharu Nakashima, Hiroshi Kitoh, Junji Kamizono, Takenobu Katagiri, Hideto Saijo, Sho Tsukamoto, Yusuke Shinoda, Ryoko Sawada, Yasuo Nakahara
    Fibrodysplasia ossificans progressiva (FOP) is a rare genetic skeletal disorder manifesting progressive heterotopic ossification (HO) and congenital malformation of the great toes. Since 2007, we have conducted research on FOP. Here, we review the findings on FOP published to date, including the results of our research. Epidemiological studies in Japan have indicated that FOP has nearly the same prevalence in Japan as in the rest of the world. Basic research on its pathoetiology has progressed rapidly since the identification of the causal gene in 2006. Clinical and radiological findings have been thoroughly researched, including early radiological signs, and diagnostic criteria were established, designating FOP as an intractable disease in Japan. In patients with FOP, the progression of HO is associated with numerous disabilities, often manifesting in vicious cycles that can lead to early mortality. Through cross-sectional and short-term longitudinal studies, we have explored patient education, quality of life, and activities of daily living among Japanese patients. The management of FOP requires education of patients and caregivers, the use of medications to settle inflammation and flare-ups, instructions to ensure proper oral care, and other compensatory approaches that aid in rehabilitation. An avoidance of medical intervention, which may cause HO to progress, is also important. The advent of new drugs to prevent HO could have clinical benefit.
    Jan. 2020, Pediatrics international : official journal of the Japan Pediatric Society, 62(1) (1), 3 - 13, English, International magazine
    Scientific journal

  • Yusuke Shinoda, Hiroshi Kobayashi, Masako Kaneko, Satoru Ohashi, Masahiko Bessho, Naoto Hayashi, Hiroyuki Oka, Jungo Imanishi, Ryoko Sawada, Koichi Ogura, Sakae Tanaka, Nobuhiko Haga, Hirotaka Kawano
    BACKGROUND: It is important to assess the fracture risk associated with metastasis in the proximal femur. The study aimed to clarify the effect of tumor location on the risk of pathological fracture of the proximal femur and investigate the fracture risk not only in the stance-loading configuration (SC), but also in the fall-loading configuration (FC) using a computed tomography (CT)-based finite element (FE) method based on a simulated metastatic model. METHODS: The axial CT scans of the proximal femora of non-osteoporotic healthy men (n = 4; age range, 42-48 years) and osteoporotic post-menopausal women (n = 4; age range, 69-78 years) were obtained with a calibration phantom, from which the three-dimensional FE models were constructed. A single 15-mm-diameter spherical void simulating a tumor was created at various locations from the neck to subtrochanteric level. Nonlinear FE analyses were performed. RESULTS: The mean predicted fracture loads without spherical voids in the SC were 7700 N in men and 4370 N in women. With the void at the medial femoral neck and in the region anteromedial to lesser trochanter, the mean predicted fracture load significantly reduced to 51.3% and 59.4% in men and 34.1% and 64.5% in women, respectively. The mean predicted fracture loads without a spherical void in the FC were 2500 N in men and 1862 N in women. With the void at the medial and posterior femoral neck, the predicted fracture load was significantly reduced to 65.7% and 79.7% in men and 48.3% and 65.4% in women, respectively. CONCLUSIONS: These results showed that the risk of pathologic fracture was quite high in both the SC and FC when the lytic lesion existed along the principal compressive trabecular trajectory or posterior neck. Prophylactic intervention should be considered for metastases at these locations.
    Nov. 2019, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 24(6) (6), 1074 - 1080, English, Domestic magazine
    Scientific journal

  • Yusuke Shinoda, Ryoko Sawada, Futaba Yoshikawa, Takahiro Oki, Toshihide Hirai, Hiroshi Kobayashi, Ko Matsudaira, Hiroyuki Oka, Sakae Tanaka, Hirotaka Kawano, Nobuhiko Haga
    Treatment for bone metastases aims to preserve patients' quality of life (QOL). Therefore, assessment of patients' reported QOL is important, especially in this field. This cross-sectional study sought to investigate the clinical factors of QOL in patients with bone metastasis in different cancer settings, at any treatment status, and examined the effect of these factors on systemic symptoms and psychological disorders. This study was conducted by a multidisciplinary team for bone metastases at a university hospital in Japan. One-hundred seventy-four patients who could complete the self-report questionnaires were selected. The questionnaire included the EQ-5D, EORTC QLQ-C15-PAL, BM22, and K6 distress scale. We obtained clinical data on tumor progression, bone metastasis, pain, and ECOG-PS. The mean (SD) EQ-5D score was 0.58 (0.24), which was lower than that of the general Japanese and US population (0.85). Skeletal-related events (SREs), pain, and ECOG-PS were significantly related to lower EQ-5D scores in the multivariable analysis (p < 0.01), whereas primary lesion or expected prognosis at the first examination was not. These three factors were also related to systemic symptoms and emotional functioning. Radiologically lytic bone metastasis and lower limb/acetabular metastases were related to SREs and ECOG-PS, respectively. In conclusion, for improving the QOL of patients with bone metastases, we should focus on SRE prevention, treatment for pain, and modifying ADL, and a multidisciplinary team might be useful.
    Oct. 2019, Clinical & experimental metastasis, 36(5) (5), 441 - 448, English, International magazine
    Scientific journal

  • Toshihide Hirai, Yusuke Shinoda, Ryosuke Tateishi, Yoshinari Asaoka, Koji Uchino, Taijiro Wake, Hiroshi Kobayashi, Masachika Ikegami, Ryoko Sawada, Nobuhiko Haga, Kazuhiko Koike, Sakae Tanaka
    BACKGROUND: With the improvement in survival of hepatocellular carcinoma patients, extrahepatic metastases have become a more frequent complication. Although pathological fractures or paralysis due to bone metastases deteriorate the quality of life of patients, no treatment guideline for bone metastases has been established. This study aimed to clarify the risk factors for these events and the clinical course of patients with bone metastases. METHODS: Out of 783 hepatocellular carcinoma patients treated in our institution between 2009 and 2016, 76 patients with bone metastases were enrolled. They were divided into two groups by the trigger of bone metastases detection. One was those diagnosed by surveillance (surveillance group), and the other was those based on symptom presentation (non-surveillance group). We investigated the clinical features, risk factors for fractures or paralysis and prognostic factors for survival after bone metastases. RESULTS: Baseline characteristics and survival were not significantly different between two groups. Fractures or paralysis occurred in 10 patients (13.2%), and the frequency was significantly higher in the non-surveillance group (20.9%) than the surveillance group (3.0%) in univariate analysis (p = 0.036). The median survival after diagnosis of bone metastases was 11.7 months. Age over 75 years (p = 0.002), hepatitis C-virus etiology (p = 0.007) and Child-Pugh class B/C (p < 0.001) were significantly associated with a shorter survival in multivariate analysis, but fractures or paralysis did not affect the survival. CONCLUSIONS: Early diagnosis through surveillance for hepatocellular carcinoma bone metastases may prevent fractures or paralysis and lead to a better quality of life for these patients.
    Jun. 2019, Japanese journal of clinical oncology, 49(6) (6), 529 - 536, English, International magazine
    Scientific journal

  • Toshihide Hirai, Hiroshi Kobayashi, Toru Akiyama, Tomotake Okuma, Hiroyuki Oka, Yusuke Shinoda, Masachika Ikegami, Yusuke Tsuda, Takashi Fukushima, Takahiro Ohki, Yuki Ishibashi, Ryoko Sawada, Takahiro Goto, Sakae Tanaka
    BACKGROUND: Schwannomas are well-encapsulated, benign neoplasms, and enucleation is a standard operation procedure. The incidence of neurological complications after surgical treatment for schwannomas of the extremities varies, and there is no consensus concerning predictive factors for complications. The aim of this study was to elucidate predictive factors for complications after surgical treatment of schwannomas that develop in the major nerves of the extremities. METHODS: A total of 139 patients with 141 schwannomas arising in major nerves were retrospectively analyzed. Data regarding preoperative clinical features, the postoperative neurological complications, and clinical course of complications, with a median follow-up period of 2 months (range, 0.5-96), were obtained. Predictive factors for complications were statistically analyzed. RESULTS: Postoperative complications occurred in 49 lesions (34.8%), including 42 with sensory disturbance and 8 with motor weakness. In univariate analysis, older age, tumors originating from the upper extremity, and major motor nerve involvement were associated with a higher complication rate (p = 0.03, p = 0.003, and p = 0.001, respectively). In multivariate analysis, major motor nerve involvement was an independent predictive factor for postoperative complications (p = 0.03). Almost all complications gradually improved, but 6 out of 8 patients with motor weakness did not show full recovery at the final follow-up. CONCLUSIONS: Schwannomas originating from major motor nerves can lead to a higher risk for postoperative complications.
    Apr. 2019, BMC musculoskeletal disorders, 20(1) (1), 166 - 166, English, International magazine
    Scientific journal

  • Hiroshi Kobayashi, Tomotake Okuma, Hiroyuki Oka, Koichi Okajima, Yuki Ishibashi, Liuzhe Zhang, Toshihide Hirai, Takahiro Ohki, Yusuke Tsuda, Masachika Ikegami, Ryoko Sawada, Yusuke Shinoda, Toru Akiyama, Hirotaka Kawano, Takahiro Goto, Sakae Tanaka
    BACKGROUND: Despite the clinical benefits of eribulin on overall survival of advanced soft tissue sarcoma (STS) patients, treatment-related toxicity reduces their QOL. Body composition metrics (BCMs) are associated with poor outcome and drug toxicities in several cancers. This study investigated whether BCMs could predict drug toxicity occurrence in advanced STS patients treated with eribulin. METHODS: This study included 23 advanced STS patients treated with eribulin between March 2016 and April 2018. BCMs were evaluated using a CT scan obtained within 1 month before or after treatment initiation. The relationship of BCMs and other clinical factors was evaluated and CART analysis used to develop classification models for risk groups of drug toxicity. RESULTS: Sixteen patients (69.6%) experienced any grade 3/4 toxicity. Eleven patients (47.8%) developed G4 hematologic toxicity, which was significantly higher in those with low skeletal muscle gauge (SMG) (P = 0.02) and low pretreatment neutrophil count (P = 0.0002). Six patients (26.1%) had grade 3/4 non-hematologic toxicity, and was higher in those with low SMG (P = 0.004), and low serum albumin level (P = 0.02). Five patients with high BMI (P = 0.03) experienced febrile neutropenia (FN) and low pretreatment neutrophil count (P = 0.02). CART analysis classified three risk groups, and area under the receiver operating characteristic curve (AUROCC) was 0.92, 0.88, 0.92 in G4 hematologic AE, G3/4 non-hematologic AE, FN, respectively. CONCLUSIONS: SMG is a significant predictive factor of eribulin drug toxicity in advanced STS patients. Risk classification of drug toxicity through combining predictive factors, could improve the therapeutic strategy used in chemotherapy.
    Apr. 2019, International journal of clinical oncology, 24(4) (4), 437 - 444, English, Domestic magazine
    Scientific journal

  • Minako Saito, Hidenori Kage, Takahiro Ando, Ryoko Sawada, Yosuke Amano, Yasushi Goto, Yusuke Shinoda, Takahide Nagase
    According to lung cancer guidelines, positron emission tomography scan is recommended for initial evaluation of bone metastasis. However, guidelines differ in their recommendations for when it should be used. We investigated the appropriate use of bone imaging in nonsmall cell lung cancer (NSCLC) patients. One hundred seventy-seven consecutive NSCLC patients who had distant metastases at presentation and were admitted between January 2012 and April 2016 were retrospectively reviewed. Among patients with bone metastases, we explored bone pain, number of bone metastases, location of bone metastases, and clinical tumor (T) and lymph node (N) classification. Sixty-three patients had bone metastases. There was a trend toward an increase in prevalence of bone metastases as lymph node stage increased. The prevalence of bone pain significantly decreased as N stage increased (p = 0.017). N0 and N2-3 patients were more likely to have multiple bone metastases (p = 0.038). Compared with patients who had a single bone metastasis, patients with multiple metastases had a significantly higher probability of having at least 1 bone metastasis located in the thorax or upper abdomen. All N0 patients have at least 1 bone metastasis in the thorax or upper abdomen. Clinical N0 NSCLC patients with bone metastasis are likely to have bone pain and have multiple bone metastases. N2-3 patients are more likely to have bone metastases but less likely to have bone pain. If NSCLC patients do not have bone pain, and CT of the chest and upper abdomen does not reveal any lymph node or bone metastasis, further survey for bone metastases may be omitted; bone imaging should be performed in N2 and N3 patients regardless of symptoms.
    Feb. 2019, Current problems in cancer, 43(1) (1), 86 - 91, English, International magazine
    Scientific journal

  • Hiroshi Kobayashi, Tomotake Okuma, Hiroyuki Oka, Toshihide Hirai, Takahiro Ohki, Masachika Ikegami, Ryoko Sawada, Yusuke Shinoda, Toru Akiyama, Kenji Sato, Satoshi Abe, Hirotaka Kawano, Takahiro Goto, Sakae Tanaka
    BACKGROUND: Pazopanib is a multi-tyrosine kinase inhibitor that is used to treat advanced soft-tissue sarcoma, and its efficacy has been confirmed in several clinical trials, although no clinically useful biomarkers have been identified. In other cancers, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the lymphocyte-to-monocyte ratio (LMR) are associated with chemotherapy response and prognosis. Therefore, we aimed to evaluate the associations of pazopanib response with NLR, PLR, and LMR among patients with advanced soft-tissue sarcoma. METHODS: Data regarding NLR, PLR, and LMR were obtained for 25 patients who received pazopanib for soft-tissue sarcoma. The patients were categorized according to their values for NLR (≥3.8 vs. <3.8), PLR (≥230 vs. <230), and LMR (≥2.4 vs. <2.4), and we evaluated the associations of these markers with progression-free survival and overall survival using Kaplan-Meier curves and Cox proportional models. RESULTS: No significant differences in progression-free survival or overall survival were observed based on the pre-treatment NLR, PLR, and LMR values. However, decreased NLR values after treatment using pazopanib were independently associated with significantly prolonged progression-free survival (hazard ratio: 0.07, p = 0.001) and overall survival (hazard ratio: 0.17, p = 0.0006). CONCLUSIONS: Decreased NLR values after treatment using pazopanib may predict high efficacy and favorable outcomes among patients with advanced soft-tissue sarcoma.
    Apr. 2018, International journal of clinical oncology, 23(2) (2), 368 - 374, English, Domestic magazine
    Scientific journal

  • Yusuke Tsuda, Tohru Nakagawa, Yusuke Shinoda, Atsushi Kanatani, Taketo Kawai, Satoru Taguchi, Yukio Yamada, Ryoko Sawada, Haruki Kume, Yukio Homma, Sakae Tanaka, Hirotaka Kawano
    BACKGROUND: The aim of the present study was to elucidate the details of bone metastasis (BM) and the resulting skeletal-related events (SREs), and survival and prognostic factors, in urothelial cancer (UC) patients with BM. METHODS: A total of 48 UC patients with BM who were treated at our institution between 1994 and 2013 were enrolled. Details of BM and SREs were investigated. The Kaplan-Meier method was used to estimate survival duration. Relationships between several clinical features and survival were analyzed using the log-rank test and the Cox hazard model. RESULTS: Of the 48 patients, 39 (81.3%) were male, with a median age at diagnosis of BM of 68 years [interquartile range (IQR), 61-75 years]. Frequent metastatic sites included the pelvis (31 patients, 64.6%) and spine (28, 58.3%). SREs occurred in 31 patients (64.6%) at a median duration of 0.9 months (IQR, 0.3-5.4 months) after diagnosis of BM, including radiation therapy (n = 23; 74.2%), spinal cord compression (n = 4; 12.9%), pathological fracture (n = 3; 9.7%) and hypercalcemia (n = 1; 3.2%). Median overall survival periods after diagnosis of BM and SREs were 6.2 and 5.6 months, respectively. On multivariate analysis, factors significantly associated with survival after BM were performance status [hazard ratio (HR) for ≥2 vs. 0-1, 4.94; P = 0.0003], liver metastasis (HR, 4.08; P = 0.0018), chemotherapy after BM (HR, 0.31; P = 0.0018), and use of bone-modifying agents (HR, 0.36; P = 0.0147). CONCLUSIONS: We revealed clinicopathological factors that are predictive of prognosis of UC patients with BM. Although the prognosis is poor, chemotherapy and bone-modifying agents may confer survival benefits.
    Jun. 2017, International journal of clinical oncology, 22(3) (3), 548 - 553, English, Domestic magazine
    Scientific journal

  • Ryoko Sawada, Yusuke Shinoda, Aya Niimi, Tohru Nakagawa, Masachika Ikegami, Hiroshi Kobayashi, Sakae Tanaka, Yukio Homma, Nobuhiko Haga
    Metastasis may occur in any bone but more commonly occurs in the spine, pelvis, or other axial bones. Metastasis in peripheral bones located distal to the elbow or knee, so-called acrometastasis, is rare. Although the mechanism of acrometastasis development is not completely understood, it is thought to be the result of a massive dissemination of cancer cells; thus the prognosis of patients with acrometastasis is relatively poor. Here, we report the case of renal pelvic cancer with multiple acrometastases in both the upper and lower extremities without axial bone metastasis in a 68-year-old man. After two regimens of chemotherapy, he suffered from pain on his wrist and ankle and swelling and hemorrhage of his toe. He had no axial bone metastasis by CT but was diagnosed with multiple acrometastases by plain radiographs. Radiation therapy and disarticulation of the left big toe at the metacarpal-phalangeal joint were performed and his pain and hemorrhage were successfully controlled. Although acrometastasis from renal pelvic cancer is very rare, we should recognize that acrometastasis might occur which exists outside of the CT scanning field.
    2017, Case reports in urology, 2017, 7830207 - 7830207, English, International magazine

  • Koichi Ogura, Ryoko Miyake, Shuichiro Shiina, Yusuke Shinoda, Tomotake Okuma, Hiroshi Kobayashi, Takahiro Goto, Kozo Nakamura, Hirotaka Kawano
    A 64-year-old man with 6-year history of hepatocellular carcinoma (HCC) was referred to us regarding bone metastasis to the right proximal femur. Although he underwent radiotherapy for pain palliation and local tumor control, the pain persisted and the tumor relapsed 3 months after the radiotherapy and he was thought to be at high risk of pathologic fracture. Given hypervascularity and large tumor size, a prophylactic internal fixation combined with adjuvant radiofrequency ablation (RFA) was proposed to reduce blood loss and prevent viable tumor cells being disseminated. His postoperative course was uneventful without requiring blood transfusion and preoperative symptoms immediately disappeared after surgery. He became capable of weight-bearing walk with a single cane and was almost asymptomatic without local progression on the plain radiographs when he died 14 months after surgery. Combination therapy of RFA and internal fixation using intramedullary nailing for metastases of the long bones from HCC seems to be a very promising technique both for sufficient pain relief and for local control of the tumor. Adjuvant RFA may become a potential option for patients with metastases of the long bones for the purpose of prevention of tumor dissemination and reduction of intraoperative blood loss.
    Aug. 2012, International journal of clinical oncology, 17(4) (4), 417 - 21, English, Domestic magazine
    Scientific journal

■ MISC
  • WADA Yuka
    THE CENTRAL JAPAN ASSOCIATION OF ORTHOPAEDIC SURGERY AND TRAUMATOLOGY, 01 Mar. 2024, The Central Japan Journal of Orthopaedic Surgery & Traumatology, 67(2) (2), 167 - 168, Japanese

  • 石橋 祐貴, 小林 寛, 岡嶋 晃一, 津田 祐輔, 大木 孝裕, 篠田 裕介, 澤田 良子, 田中 栄
    (公社)日本整形外科学会, Mar. 2024, 日本整形外科学会雑誌, 98(2) (2), S417 - S417, Japanese

  • 澤田 良子, 篠田 裕介, 大木 孝裕, 石橋 祐貴, 小林 寛, 松林 嘉孝, 田中 栄, 芳賀 信彦
    (公社)日本整形外科学会, Mar. 2024, 日本整形外科学会雑誌, 98(2) (2), S465 - S465, Japanese

  • 原 仁美, 深瀬 直政, 澤田 良子, 藤原 周一, 宮本 智弘, 中松 裕太, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Mar. 2024, 日本整形外科学会雑誌, 98(2) (2), S530 - S530, Japanese

  • 骨転移患者に対するリハビリテーション治療効果 傾向スコアマッチングを用いた検討
    吉川 遼, 藤井 康光, 大西 宏和, 津田 悠三, 中村 謙, 鹿島 遼河, 佐保 航, 原田 理沙, 武岡 由樹, 澤田 良子, 深瀬 直政, 原 仁美, 角谷 賢一朗, 秋末 敏宏, 黒田 良祐, 酒井 良忠
    (公社)日本リハビリテーション医学会, Oct. 2023, The Japanese Journal of Rehabilitation Medicine, 60(秋季特別号) (秋季特別号), S355 - S355, Japanese

  • 左第2肋骨に生じた骨軟骨腫を胸腔鏡補助下に摘出した一例
    和田 悠花, 原 仁美, 澤田 良子, 田中 雄悟, 黒田 良祐, 秋末 敏宏
    (一社)中部日本整形外科災害外科学会, Oct. 2023, 中部日本整形外科災害外科学会雑誌, 66(秋季学会) (秋季学会), 318 - 318, Japanese

  • 宮本 智弘, 藤原 周一, 原 仁美, 深瀬 直政, 澤田 良子, 八尋 俊輔, 青井 貴之, 小柳 三千代, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Aug. 2023, 日本整形外科学会雑誌, 97(8) (8), S1892 - S1892, Japanese

  • 藤原 周一, 河本 旭哉, 原 仁美, 深瀬 直政, 澤田 良子, 八尋 俊輔, 宮本 智弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1382 - S1382, Japanese

  • 宮本 智弘, 藤原 周一, 河本 旭哉, 原 仁美, 深瀬 直政, 澤田 良子, 八尋 俊輔, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1435 - S1435, Japanese

  • 深瀬 直政, 藤原 周一, 竹森 俊幸, 出水 祐介, 沖本 智昭, 澤田 良子, 原 仁美, 河本 旭哉, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1439 - S1439, Japanese

  • 竹森 俊幸, 河本 旭哉, 藤田 郁夫, 藤本 卓也, 原 仁美, 深瀬 直政, 澤田 良子, 藤原 周一, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1440 - S1440, Japanese

  • 竹森 俊幸, 河本 旭哉, 藤田 郁夫, 藤本 卓也, 原 仁美, 深瀬 直政, 澤田 良子, 藤原 周一, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Mar. 2023, 日本整形外科学会雑誌, 97(3) (3), S957 - S957, Japanese

  • 竹森 俊幸, 河本 旭哉, 藤田 郁夫, 藤本 卓也, 原 仁美, 深瀬 直政, 澤田 良子, 藤原 周一, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Mar. 2023, 日本整形外科学会雑誌, 97(3) (3), S957 - S957, Japanese

  • 内軟骨腫との鑑別を要した小児中足骨発生の類上皮血管内皮腫の1例
    山本 顕, 藤原 周一, 原 仁美, 深瀬 直政, 澤田 良子, 黒田 良祐, 河本 旭哉, 秋末 敏宏
    (一社)中部日本整形外科災害外科学会, Sep. 2022, 中部日本整形外科災害外科学会雑誌, 65(5) (5), 746 - 746, Japanese

  • 澤田 良子
    (株)医学書院, Oct. 2021, 臨床整形外科, 56(10) (10), 1283 - 1287, Japanese

  • 各科臨床のトピックス 転移性骨腫瘍の診断と治療
    澤田 良子
    (公社)日本医師会, Oct. 2021, 日本医師会雑誌, 150(7) (7), 1224 - 1225, Japanese

  • 澤田 良子, 篠田 裕介, 大木 孝裕, 張 劉哲, 津田 祐輔, 小林 寛, 緒方 徹, 田中 栄, 芳賀 信彦
    東日本整形災害外科学会, Aug. 2021, 東日本整形災害外科学会雑誌, 33(3) (3), 249 - 249, Japanese

  • 小林 寛, 秋山 達, 岡嶋 晃一, 張 劉哲, 平井 利英, 大木 孝裕, 池上 政周, 澤田 良子, 津田 祐輔, 大隈 知威, 篠田 裕介, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1259 - S1259, Japanese

  • 小林 寛, 秋山 達, 岡嶋 晃一, 張 劉哲, 平井 利英, 大木 孝裕, 池上 政周, 澤田 良子, 津田 祐輔, 大隈 知威, 篠田 裕介, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1259 - S1259, Japanese

  • CT横断像を用いた下肢骨転移病的骨折リスク因子の解析
    篠田 裕介, 澤田 良子, 大木 孝裕, 秋山 達, 田中 栄, 芳賀 信彦
    (公社)日本リハビリテーション医学会, May 2021, The Japanese Journal of Rehabilitation Medicine, 58(特別号) (特別号), 2 - 1, Japanese

  • 腫瘍性低リン血症性骨軟化症の難治症例に対するリハビリテーション治療
    大木 孝裕, 澤田 良子, 西坂 智佳, 遠藤 聡, 井口 はるひ, 唐沢 康暉, 藤原 清香, 篠田 裕介, 芳賀 信彦
    (公社)日本リハビリテーション医学会, Nov. 2020, The Japanese Journal of Rehabilitation Medicine, 57(秋季特別号) (秋季特別号), S346 - S346, Japanese

  • 骨転移の痛みのマネージメント 骨転移に対する診療科横断的・集学的治療の重要性
    篠田 裕介, 澤田 良子, 大木 孝裕, 芳賀 信彦, 河野 博隆, 住谷 昌彦, 岩瀬 哲, 金井 良晃
    (NPO)日本緩和医療学会, Aug. 2020, Palliative Care Research, 15(Suppl.) (Suppl.), S38 - S38, Japanese

  • 大木 孝裕, 澤田 良子, 岡嶋 晃一, 石橋 祐貴, 平井 利英, 小林 寛, 大隈 知威, 篠田 裕介, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1396 - S1396, Japanese

  • 平井 利英, 小林 寛, 大隈 知威, 石橋 祐貴, 池上 政周, 大木 孝裕, 澤田 良子, 篠田 裕介, 岡嶋 晃一, 張 劉哲, 秋山 達, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1413 - S1413, Japanese

  • 池上 政周, 小林 寛, 篠田 裕介, 大木 孝裕, 五嶋 孝博, 澤田 良子, 大隈 知威, 石橋 祐貴, 岡嶋 晃一, 平井 利英, 田中 栄
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1444 - S1444, Japanese

  • 小林 寛, 大隈 知威, 平井 利英, 岡嶋 晃一, 張 劉哲, 石橋 祐貴, 大木 孝裕, 池上 政周, 澤田 良子, 篠田 裕介, 秋山 達, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1444 - S1444, Japanese

  • 篠田 裕介, 澤田 良子, 大木 孝裕, 石橋 祐貴, 小林 寛, 平井 利英, 岡嶋 晃一, 大隈 知威, 五嶋 孝博, 張 劉哲, 秋山 達, 芳賀 信彦, 田中 栄
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1469 - S1469, Japanese

  • 澤田 良子, 篠田 裕介, 大木 孝裕, 石橋 祐貴, 小林 寛, 松林 嘉孝, 岡嶋 晃一, 平井 利英, 大隈 知威, 五嶋 孝博, 田中 栄, 芳賀 信彦
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1478 - S1478, Japanese

  • 高宮 章裕, 小林 寛, 石橋 祐貴, 牧瀬 尚大, 大木 孝裕, 澤田 良子, 篠田 裕介, 牛久 哲男, 田中 栄
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1518 - S1518, Japanese

  • 上地 新, 石橋 祐貴, 牧瀬 尚大, 大木 孝裕, 澤田 良子, 篠田 裕介, 牛久 哲男, 田中 栄, 小林 寛
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1520 - S1520, Japanese

  • 石橋 祐貴, 小林 寛, 大木 孝裕, 澤田 良子, 篠田 裕介, 岡嶋 晃一, 平井 利英, 大隈 知威, 張 劉哲, 秋山 達, 田中 栄
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1542 - S1542, Japanese

  • 小嶌 宏典, 石橋 祐貴, 大木 孝裕, 澤田 良子, 篠田 裕介, 田中 栄, 小林 寛
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1574 - S1574, Japanese

  • がん患者の運動器障害とリハビリテーション治療 がん患者の運動器障害 総論
    篠田 裕介, 澤田 良子, 大木 孝裕, 芳賀 信彦
    (公社)日本リハビリテーション医学会, Jul. 2020, The Japanese Journal of Rehabilitation Medicine, 57(特別号) (特別号), S481 - S481, Japanese

  • 終末期脊椎転移患者におけるトイレ歩行の実態調査
    澤田 良子, 篠田 裕介, 大木 孝裕, 田中 栄, 芳賀 信彦
    (公社)日本リハビリテーション医学会, Jul. 2020, The Japanese Journal of Rehabilitation Medicine, 57(特別号) (特別号), 3 - 4, Japanese

  • 脊椎転移の手術後の自宅退院に影響する因子 DPCデータベースを用いた検討
    澤田 良子, 山名 隼人, 篠田 裕介, 小林 寛, 松林 嘉孝, 津田 祐輔, 大木 孝裕, 石橋 祐貴, 康永 秀生, 田中 栄, 芳賀 信彦
    (公社)日本整形外科学会, Mar. 2020, 日本整形外科学会雑誌, 94(3) (3), S1098 - S1098, Japanese

  • 石橋 祐貴, 小林 寛, 岡嶋 晃一, 平井 利英, 大隈 知威, 五嶋 孝博, 大木 孝弘, 澤田 良子, 篠田 裕介, 秋山 達, 張 劉哲, 田中 栄
    (公社)日本整形外科学会, Mar. 2020, 日本整形外科学会雑誌, 94(3) (3), S776 - S776, Japanese

  • 澤田 良子, 山名 隼人, 篠田 裕介, 小林 寛, 松林 嘉孝, 津田 祐輔, 大木 孝裕, 石橋 祐貴, 康永 秀生, 田中 栄, 芳賀 信彦
    (公社)日本整形外科学会, Mar. 2020, 日本整形外科学会雑誌, 94(3) (3), S1098 - S1098, Japanese

  • 平井 利英, 小林 寛, 池上 政周, 篠田 裕介, 澤田 良子, 田中 栄
    (一社)日本骨代謝学会, Sep. 2019, 日本骨代謝学会学術集会プログラム抄録集, 37回, 195 - 195, Japanese

  • 骨転移キャンサーボードNOW 骨転移患者のQOLに影響する因子
    篠田 裕介, 芳賀 信彦, 澤田 良子, 大木 孝裕, 平井 利英, 小林 寛, 田中 栄, 河野 博隆
    関東整形災害外科学会, Aug. 2019, 関東整形災害外科学会雑誌, 50(4) (4), 233 - 233, Japanese

  • 澤田 良子, 篠田 裕介, 大木 孝裕, 石橋 祐貴, 小林 寛, 田中 栄, 芳賀 信彦
    東日本整形災害外科学会, Aug. 2019, 東日本整形災害外科学会雑誌, 31(3) (3), 245 - 245, Japanese

  • 骨転移キャンサーボードNOW 骨転移患者のQOLに影響する因子
    篠田 裕介, 芳賀 信彦, 澤田 良子, 大木 孝裕, 平井 利英, 小林 寛, 田中 栄, 河野 博隆
    関東整形災害外科学会, Aug. 2019, 関東整形災害外科学会雑誌, 50(4) (4), 233 - 233, Japanese

  • 転移性骨腫瘍と就労
    澤田 良子, 大木 孝裕, 篠田 裕介, 河野 博隆, 平井 利英, 小林 寛, 田中 栄
    関東整形災害外科学会, Aug. 2019, 関東整形災害外科学会雑誌, 50(4) (4), 236 - 236, Japanese

  • 篠田 裕介, 澤田 良子, 大木 孝裕, 平井 利英, 小林 寛, 田中 栄, 芳賀 信彦
    日本運動器科学会, Jun. 2019, 運動器リハビリテーション, 30(2) (2), 131 - 131, Japanese

  • 篠田 裕介, 澤田 良子, 大木 孝裕, 平井 利英, 小林 寛, 石橋 祐貴, 岡嶋 晃一, 大隈 知威, 五嶋 孝博, 張 劉哲, 秋山 達, 芳賀 信彦, 田中 栄
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1378 - S1378, Japanese

  • 小林 寛, 大隈 知威, 秋山 達, 岡嶋 晃一, 張 劉哲, 石橋 祐貴, 平井 利英, 大木 孝裕, 池上 政周, 澤田 良子, 津田 祐輔, 篠田 裕介, 岡 敬之, 河野 博隆, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1392 - S1392, Japanese

  • 荒木 岳, 平井 利英, 小林 寛, 大木 孝裕, 澤田 良子, 篠田 裕介, 田中 栄
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1554 - S1554, Japanese

  • 大木 孝裕, 澤田 良子, 岡嶋 晃一, 石橋 祐貴, 平井 利英, 小林 寛, 大隈 知威, 篠田 裕介, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1556 - S1556, Japanese

  • 澤田 良子
    (株)医学書院, May 2019, 臨床整形外科, 54(5) (5), 465 - 468, Japanese

  • 骨転移癌の治療選択-キャンサーボードの運用について- 骨転移キャンサーボードの役割とリハビリテーションの実際
    篠田 裕介, 澤田 良子, 大木 孝裕, 平井 利英, 小林 寛, 田中 栄, 芳賀 信彦
    日本外科系連合学会, May 2019, 日本外科系連合学会誌, 44(3) (3), 533 - 533, Japanese

  • 対麻痺・膀胱直腸障害で発症した骨原発悪性リンパ腫の1例
    大木 孝裕, 澤田 良子, 篠田 裕介, 芳賀 信彦
    (公社)日本リハビリテーション医学会, May 2019, The Japanese Journal of Rehabilitation Medicine, 56(特別号) (特別号), 1 - 3, Japanese

  • 転移性骨腫瘍と就労
    澤田 良子, 篠田 裕介, 大木 孝裕, 平井 利英, 小林 寛, 河野 博隆, 田中 栄, 芳賀 信彦
    関東整形災害外科学会, Mar. 2019, 関東整形災害外科学会雑誌, 50(臨増号外) (臨増号外), 59 - 59, Japanese

  • 骨転移キャンサーボードNOW 骨転移患者のQOLに影響する因子
    篠田 裕介, 澤田 良子, 大木 孝裕, 平井 利英, 小林 寛, 河野 博隆, 田中 栄, 芳賀 信彦
    関東整形災害外科学会, Mar. 2019, 関東整形災害外科学会雑誌, 50(臨増号外) (臨増号外), 84 - 84, Japanese

  • 澤田 良子, 山名 隼人, 篠田 裕介, 津田 祐輔, 小林 寛, 松林 嘉孝, 田中 栄, 康永 秀夫, 芳賀 信彦
    (公社)日本整形外科学会, Mar. 2019, 日本整形外科学会雑誌, 93(3) (3), S1057 - S1057, Japanese

  • がん骨転移のリハビリテーション:機能予後と生命予後 骨転移のリハビリテーション チーム医療の重要性
    篠田 裕介, 澤田 良子, 大木 孝裕, 河野 博隆, 田中 栄, 芳賀 信彦
    (公社)日本リハビリテーション医学会, Oct. 2018, The Japanese Journal of Rehabilitation Medicine, 55(秋季特別号) (秋季特別号), S214 - S214, Japanese

  • 篠田 裕介, 澤田 良子, 平井 利英, 小林 寛, 田中 栄, 河野 博隆, 芳賀 信彦
    (一社)日本骨折治療学会, Jul. 2018, 骨折, 40(Suppl.) (Suppl.), S37 - S37, Japanese

  • 緩和ケアとがんロコモ～がん治療における運動器診療との連携～ 緩和ケアにおける骨転移キャンサーボードの役割
    篠田 裕介, 澤田 良子, 金井 良晃, 住谷 昌彦, 河野 博隆, 岩瀬 哲, 芳賀 信彦
    (NPO)日本緩和医療学会, Jun. 2018, Palliative Care Research, 13(Suppl.) (Suppl.), S151 - S151, Japanese

  • 小林 寛, 高阪 真路, 平井 利英, 澤田 良子, 池上 政周, 篠田 裕介, 牛久 綾, 牛久 哲男, 深山 正久, 間野 博行, 田中 栄
    (公社)日本整形外科学会, Jun. 2018, 日本整形外科学会雑誌, 92(6) (6), S1386 - S1386, Japanese

  • 高橋 雅人, 中平 有, 澤田 良子, 小林 寛, 篠田 裕介, 芳賀 信彦
    (公社)日本整形外科学会, Jun. 2018, 日本整形外科学会雑誌, 92(6) (6), S1522 - S1522, Japanese

  • 有限要素法を用いた転倒条件における大腿骨近位部骨折のリスク評価
    篠田 裕介, 澤田 良子, 藤原 清香, 井口 はるひ, 唐沢 康暉, 河野 博隆, 田中 栄, 芳賀 信彦
    (公社)日本リハビリテーション医学会, May 2018, The Japanese Journal of Rehabilitation Medicine, 55(特別号) (特別号), 3 - 2, Japanese

  • 小林 寛, 高阪 真路, 平井 利英, 澤田 良子, 池上 政周, 篠田 裕介, 牛久 綾, 牛久 哲男, 深山 正久, 間野 博行, 田中 栄
    (公社)日本整形外科学会, Mar. 2018, 日本整形外科学会雑誌, 92(2) (2), S100 - S100, Japanese

  • 篠田 裕介, 澤田 良子, 松林 嘉孝, 平井 利英, 小林 寛, 河野 博隆, 田中 栄, 芳賀 信彦
    (公社)日本整形外科学会, Mar. 2018, 日本整形外科学会雑誌, 92(2) (2), S484 - S484, Japanese

  • 平井 利英, 篠田 裕介, 澤田 良子, 小林 寛, 内野 康志, 浅岡 良成, 建石 良介, 小池 和彦, 田中 栄
    (公社)日本整形外科学会, Mar. 2018, 日本整形外科学会雑誌, 92(3) (3), S904 - S904, Japanese

  • 抗RANKL抗体が奏効した骨巨細胞腫に対しH3F3A遺伝子変異解析と組織学的評価を行った1例
    熊埜御堂 雄大, 池上 政周, 澤田 良子, 篠田 裕介, 小林 寛, 武冨 修治, 田中 栄
    関東整形災害外科学会, Feb. 2018, 関東整形災害外科学会雑誌, 49(1) (1), 55 - 60, Japanese

  • 抗RANKL抗体が奏功した骨巨細胞腫に対し、H3F3A遺伝子変異解析と組織学的評価を行った1例
    熊埜御堂 雄大, 池上 政周, 澤田 良子, 篠田 裕介, 小林 寛, 武冨 修治, 田中 栄
    関東整形災害外科学会, Aug. 2017, 関東整形災害外科学会雑誌, 48(4) (4), 199 - 199, Japanese

  • 急速に進行し病的骨折をきたした肺癌骨皮質内転移の1例
    澤田 良子, 篠田 裕介, 小林 寛, 池上 政周, 田中 栄
    関東整形災害外科学会, Aug. 2017, 関東整形災害外科学会雑誌, 48(4) (4), 193 - 196, Japanese

  • 平井 利英, 篠田 裕介, 澤田 良子, 池上 政周, 小林 寛, 田 翔太, 松原 全宏, 田中 栄
    (一社)日本骨折治療学会, Jul. 2017, 骨折, 39(Suppl.) (Suppl.), S239 - S239, Japanese

  • 骨転移患者の集学的ケア 骨転移診療におけるリハビリテーションの役割
    篠田 裕介, 澤田 良子, 吉川 二葉, 金井 良晃, 住谷 昌彦, 岩瀬 哲, 河野 博隆, 芳賀 信彦
    (NPO)日本緩和医療学会, Jun. 2017, Palliative Care Research, 12(Suppl.) (Suppl.), S174 - S174, Japanese

  • 小林 寛, 大隈 知威, 平井 利英, 大木 孝裕, 池上 政周, 澤田 良子, 篠田 裕介, 岡 敬之, 秋山 達, 佐藤 健二, 時崎 暢, 阿部 哲士, 河野 博隆, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jun. 2017, 日本整形外科学会雑誌, 91(6) (6), S1374 - S1374, Japanese

  • 谷 彰一郎, 森崎 裕, 上原 浩介, 澤田 良子, 小林 寛, 篠田 裕介, 河野 博隆, 田中 栄
    (公社)日本整形外科学会, Jun. 2017, 日本整形外科学会雑誌, 91(6) (6), S1404 - S1404, Japanese

  • 津田 祐輔, 康永 秀生, 小林 寛, 篠田 裕介, 澤田 良子, 池上 政周, 平井 利英, 河野 博隆
    (公社)日本整形外科学会, Jun. 2017, 日本整形外科学会雑誌, 91(6) (6), S1404 - S1404, Japanese

  • 平井 利英, 篠田 裕介, 澤田 良子, 池上 政周, 小林 寛, 石橋 祐貴, 大木 孝裕, 大隈 知威, 五嶋 孝博, 内野 康志, 浅岡 良成, 建石 良介, 小池 和彦, 田中 栄
    (公社)日本整形外科学会, Jun. 2017, 日本整形外科学会雑誌, 91(6) (6), S1410 - S1410, Japanese

  • 平井 利英, 小林 寛, 澤田 良子, 池上 政周, 篠田 裕介, 石橋 祐貴, 大木 孝裕, 大隈 知威, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jun. 2017, 日本整形外科学会雑誌, 91(6) (6), S1444 - S1444, Japanese

  • 中平 有, 高橋 雅人, 横田 一彦, 澤田 良子, 篠田 裕介, 芳賀 信彦
    (一社)日本理学療法学会連合, Apr. 2017, 理学療法学, 44(Suppl.2) (Suppl.2), P - 1, Japanese

  • 抗RANKL抗体が著効した骨巨細胞腫に対しH3F3A遺伝子変異解析と組織学的評価を行った1例
    熊埜御堂 雄大, 池上 政周, 澤田 良子, 篠田 裕介, 小林 寛, 武冨 修治, 田中 栄
    関東整形災害外科学会, Mar. 2017, 関東整形災害外科学会雑誌, 48(臨増号外) (臨増号外), 50 - 50, Japanese

  • 転移性脊椎腫瘍に対する治療 院内ボードのすゝめ
    筑田 博隆, 松林 嘉孝, 谷口 優樹, 大島 寧, 篠田 裕介, 澤田 良子, 平井 利英, 尾市 健, 田中 栄
    関東整形災害外科学会, Mar. 2017, 関東整形災害外科学会雑誌, 48(臨増号外) (臨増号外), 132 - 132, Japanese

  • 篠田 裕介, 澤田 良子, 吉川 二葉, 池上 政周, 小林 寛, 岡 敬之, 松平 浩, 田中 栄, 河野 博隆, 芳賀 信彦
    (公社)日本整形外科学会, Mar. 2017, 日本整形外科学会雑誌, 91(3) (3), S1059 - S1059, Japanese

  • 篠田 裕介, 澤田 良子, 吉川 二葉, 池上 政周, 小林 寛, 田中 栄, 鹿毛 秀宣, 田中 剛, 長瀬 隆英, 芳賀 信彦
    (NPO)日本肺癌学会, Nov. 2016, 肺癌, 56(6) (6), 780 - 780, Japanese

  • 篠田 裕介, 澤田 良子, 吉川 二葉, 小林 寛, 池上 政周, 田中 栄, 河野 博隆, 芳賀 信彦
    東日本整形災害外科学会, Aug. 2016, 東日本整形災害外科学会雑誌, 28(3) (3), 212 - 212, Japanese

  • 張 劉哲, 池上 政周, 澤田 良子, 篠原 祐介, 河野 博隆, 田中 栄, 小林 寛
    東日本整形災害外科学会, Aug. 2016, 東日本整形災害外科学会雑誌, 28(3) (3), 268 - 268, Japanese

  • 小林 寛, 秋山 達, 大隈 知威, 平井 利英, 大木 孝裕, 澤田 良子, 津田 祐輔, 池上 政周, 小倉 浩一, 今西 淳悟, 篠田 裕介, 山本 愛一郎, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2016, 日本整形外科学会雑誌, 90(6) (6), S1208 - S1208, Japanese

  • 澤田 良子, 篠田 裕介, 吉川 二葉, 大木 孝裕, 池上 政周, 小林 寛, 中井 陽介, 伊佐山 浩通, 小池 和彦, 平井 利英, 石橋 祐貴, 大隈 知威, 五嶋 孝博, 芳賀 信彦, 河野 博隆, 田中 栄
    (公社)日本整形外科学会, Jun. 2016, 日本整形外科学会雑誌, 90(6) (6), S1247 - S1247, Japanese

  • 高橋 雅人, 伊藤 智絵, 中平 有, 澤田 良子, 小林 寛, 篠田 裕介
    (公社)日本整形外科学会, Jun. 2016, 日本整形外科学会雑誌, 90(6) (6), S1290 - S1290, Japanese

  • 篠田 裕介, 澤田 良子, 吉川 二葉, 小林 寛, 池上 政周, 松平 浩, 岡 敬之, 田中 栄, 河野 博隆, 芳賀 信彦
    (公社)日本整形外科学会, Jun. 2016, 日本整形外科学会雑誌, 90(6) (6), S1292 - S1292, Japanese

  • 池上 政周, 小林 寛, 澤田 良子, 篠田 裕介, 石橋 祐貴, 平井 利英, 大隈 知威, 五嶋 孝博
    (公社)日本整形外科学会, Jun. 2016, 日本整形外科学会雑誌, 90(6) (6), S1295 - S1295, Japanese

  • 大木 孝裕, 小林 寛, 澤田 良子, 池上 政周, 篠田 裕介, 平井 利英, 大隈 知威, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jun. 2016, 日本整形外科学会雑誌, 90(6) (6), S1356 - S1356, Japanese

  • 林 玲匡, 牛久 哲男, 池上 政周, 澤田 良子, 小林 寛, 篠田 裕介, 深山 正久
    (公社)日本整形外科学会, Jun. 2016, 日本整形外科学会雑誌, 90(6) (6), S1386 - S1386, Japanese

  • がん脊椎転移の前後方向部位局在と下肢麻痺症状のMRI画像解析
    阿部 博昭, 穂積 淳, 井上 玲央, 横島 弥栄子, 篠田 裕介, 澤田 良子, 緒方 徹, 筑田 博隆, 金井 良晃, 住谷 昌彦
    (NPO)日本緩和医療学会, Jun. 2016, Palliative Care Research, 11(Suppl.) (Suppl.), S375 - S375, Japanese

  • 骨転移患者のQOL評価
    吉川 二葉, 澤田 良子, 篠田 裕介, 藤原 清香, 中原 康雄, 芳賀 信彦
    (公社)日本リハビリテーション医学会, Jun. 2016, The Japanese Journal of Rehabilitation Medicine, (JARM2016) (JARM2016), I453 - I453, Japanese

  • 骨盤骨転移症例のリハビリテーション
    篠田 裕介, 澤田 良子, 吉川 二葉, 松平 浩, 田中 栄, 河野 博隆, 芳賀 信彦
    (公社)日本リハビリテーション医学会, Jun. 2016, The Japanese Journal of Rehabilitation Medicine, (JARM2016) (JARM2016), I454 - I454, Japanese

  • 抗RANKL抗体が著効した骨巨細胞腫に対しH3F3A遺伝子変異解析を行った1例
    熊埜御堂 雄大, 池上 政周, 澤田 良子, 篠田 裕介, 武冨 修治, 田中 栄
    関東整形災害外科学会, Apr. 2016, 関東整形災害外科学会雑誌, 47(2) (2), 99 - 100, Japanese

  • 篠田 裕介, 澤田 良子, 吉川 二葉, 大木 孝裕, 小林 寛, 五嶋 孝博, 大隈 知威, 池上 政周, 田中 栄, 河野 博隆, 芳賀 信彦
    (公社)日本整形外科学会, Mar. 2016, 日本整形外科学会雑誌, 90(3) (3), S857 - S857, Japanese

  • 6年の経過で緩徐に尺骨神経麻痺をきたしたlocalized hypertrophic neuropathyの1例
    吉田 祐一, 大木 孝裕, 澤田 良子, 篠田 裕介, 河野 博隆, 田中 栄
    関東整形災害外科学会, Oct. 2015, 関東整形災害外科学会雑誌, 46(5) (5), 272 - 273, Japanese

  • 骨転移治療戦略とがんのリハビリテーション 診療科横断的なキャンサーボード(CB)診療体制による運動器マネージメントは骨転移患者のQOL維持に有用である
    篠田 裕介, 澤田 良子, 津田 祐輔, 大隈 知威, 小林 寛, 大木 孝裕, 池上 政周, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Oct. 2015, 日本整形外科学会雑誌, 89(10) (10), 763 - 767, Japanese

  • 骨転移治療戦略とがんのリハビリテーション 骨転移による大腿骨病的骨折患者の在院死亡率 DPCデータベースによる検討
    津田 祐輔, 康永 秀生, 澤田 良子, 篠田 裕介, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Oct. 2015, 日本整形外科学会雑誌, 89(10) (10), 775 - 778, Japanese

  • 津田 祐輔, 松田 浩一, 谷川 千津, 平田 真, 宮本 崇, 澤田 良子, 大木 孝裕, 小林 寛, 篠田 裕介, 河野 博隆, 田中 栄
    (公社)日本整形外科学会, Sep. 2015, 日本整形外科学会雑誌, 89(8) (8), S1796 - S1796, Japanese

  • 骨軟部 骨軟部腫瘍の診断・バイオマーカー 骨転移キャンサーボード介入がSRE発生に及ぼす効果
    篠田 裕介, 澤田 良子, 大木 孝裕, 小林 寛, 大隈 知威, 池上 政周, 平井 利英, 五嶋 孝裕, 金井 良晃, 住谷 昌彦, 岩瀬 哲, 田中 栄, 芳賀 信彦, 河野 博隆
    (一社)日本癌治療学会, Sep. 2015, 日本癌治療学会誌, 50(3) (3), 1447 - 1447, Japanese

  • 乳癌骨転移の骨転移Cancer Boardの介入 多診療科による骨転移マネージメントの実際
    西岡 琴江, 原田 真悠水, 尾辻 和尊, 佐藤 綾花, 石橋 祐子, 笹原 麻子, 菊池 弥寿子, 分田 貴子, 山村 純子, 倉林 理恵, 丹羽 隆善, 澤田 良子, 篠田 裕介, 多田 敬一郎, 瀬戸 泰之
    (一社)日本乳癌学会, Jul. 2015, 日本乳癌学会総会プログラム抄録集, 23回, 406 - 406, Japanese

  • 小林 寛, 河野 博隆, 筑田 博隆, 篠田 裕介, 澤田 良子, 大木 孝裕, 小倉 浩一, 津田 祐輔, 大隈 知威, 秋山 達, 今西 淳悟, 平田 真, 山本 愛一郎, 池上 政周, 平井 利英, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jun. 2015, 日本整形外科学会雑誌, 89(6) (6), S1205 - S1205, Japanese

  • 小林 寛, 河野 博隆, 篠田 裕介, 澤田 良子, 大木 孝裕, 小倉 浩一, 津田 祐輔, 大隈 知威, 秋山 達, 今西 淳悟, 平田 真, 山本 愛一郎, 池上 政周, 平井 利英, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Jun. 2015, 日本整形外科学会雑誌, 89(6) (6), S1217 - S1217, Japanese

  • 結節性筋膜炎の臨床像およびMR画像所見の検討
    池上 政周, 五嶋 孝博, 田中 哲平, 平井 利英, 山川 聖史, 穂積 高弘, 元井 亨, 大木 孝裕, 澤田 良子, 小林 寛, 篠田 裕介, 河野 博隆
    (公社)日本整形外科学会, Jun. 2015, 日本整形外科学会雑誌, 89(6) (6), S1231 - S1231, Japanese

  • 紡錘形細胞脂肪腫のMR画像所見と腫瘍体積倍加時間
    池上 政周, 五嶋 孝博, 田中 哲平, 平井 利英, 山川 聖史, 穂積 高弘, 元井 亨, 大木 孝裕, 澤田 良子, 小林 寛, 篠田 裕介, 河野 博隆
    (公社)日本整形外科学会, Jun. 2015, 日本整形外科学会雑誌, 89(6) (6), S1231 - S1231, Japanese

  • 吉田 俊太郎, 篠田 裕介, 成田 明子, 太田 弓子, 神宝 隆行, 澤田 良子, 大木 孝裕, 小林 寛, 芳賀 信彦, 小池 和彦, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2015, 日本整形外科学会雑誌, 89(6) (6), S1292 - S1292, Japanese

  • 西岡 琴江, 篠田 裕介, 多田 敬一郎, 澤田 良子, 小林 寛, 大木 孝裕, 芳賀 信彦, 田中 栄, 瀬戸 泰之, 河野 博隆
    (公社)日本整形外科学会, Jun. 2015, 日本整形外科学会雑誌, 89(6) (6), S1292 - S1292, Japanese

  • 篠田 裕介, 澤田 良子, 吉田 俊太郎, 小林 寛, 大木 孝裕, 成田 明子, 太田 弓子, 神宝 隆行, 平井 利英, 池上 政周, 五嶋 孝博, 芳賀 信彦, 小池 和彦, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2015, 日本整形外科学会雑誌, 89(6) (6), S1322 - S1322, Japanese

  • 平井 利英, 池上 政周, 五嶋 孝博, 大隈 知威, 山川 聖史, 穂積 高弘, 元井 亨, 大木 孝裕, 澤田 良子, 小林 寛, 篠田 裕介, 河野 博隆
    (公社)日本整形外科学会, Jun. 2015, 日本整形外科学会雑誌, 89(6) (6), S1350 - S1350, Japanese

  • 澤田 良子, 篠田 裕介, 大木 孝裕, 小林 寛, 平井 利英, 池上 政周, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2015, 日本整形外科学会雑誌, 89(6) (6), S1356 - S1356, Japanese

  • 大木 孝裕, 小林 寛, 澤田 良子, 篠田 裕介, 平井 利英, 池上 政周, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2015, 日本整形外科学会雑誌, 89(6) (6), S1373 - S1373, Japanese

  • 骨転移キャンサーボード設立後の手術症例24例の検討 整形外科医を中心とした当院の取り組みについて
    澤田 良子, 篠田 裕介, 大木 孝裕, 小林 寛, 金井 良晃, 住谷 昌彦, 岩瀬 哲, 田中 栄, 河野 博隆
    (NPO)日本緩和医療学会, Jun. 2015, 日本緩和医療学会学術大会プログラム・抄録集, 20回, 371 - 371, Japanese

  • 骨転移患者に対する骨転移キャンサーボード早期介入の意義
    篠田 裕介, 澤田 良子, 小林 寛, 大木 孝裕, 岩瀬 哲, 金井 良晃, 住谷 昌彦, 芳賀 信彦, 河野 博隆
    (NPO)日本緩和医療学会, Jun. 2015, 日本緩和医療学会学術大会プログラム・抄録集, 20回, 455 - 455, Japanese

  • 骨転移キャンサーボード早期介入により骨関連事象の発生は抑制されるか?
    篠田 裕介, 澤田 良子, 中原 康雄, 藤原 清香, 正田 奈緒子, 吉川 二葉, 井口 はるひ, 真野 浩志, 野村 恵, 小谷 博史, 田中 栄, 河野 博隆, 芳賀 信彦
    (公社)日本リハビリテーション医学会, May 2015, The Japanese Journal of Rehabilitation Medicine, 52(Suppl.) (Suppl.), S303 - S303, Japanese

  • 6年の経過で緩徐に尺骨神経麻痺をきたした神経内神経周膜腫の1例
    吉田 祐一, 大木 孝裕, 澤田 良子, 小林 寛, 篠田 裕介, 河野 博隆, 田中 栄
    関東整形災害外科学会, Mar. 2015, 関東整形災害外科学会雑誌, 46(臨増号外) (臨増号外), 88 - 88, Japanese

  • 高齢者包括的機能評価を利用した高齢軟部肉腫患者の予後因子解析
    津田 祐輔, 小林 英介, 篠田 裕介, 小倉 浩一, 小林 寛, 澤田 良子, 大木 孝裕, 田中 栄, 川井 章, 河野 博隆
    (公社)日本整形外科学会, Mar. 2015, 日本整形外科学会雑誌, 89(2) (2), S151 - S151, Japanese

  • 大木 孝裕, 澤田 良子, 小林 寛, 篠田 裕介, 平井 利英, 池上 政周, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Mar. 2015, 日本整形外科学会雑誌, 89(3) (3), S681 - S681, Japanese

  • 篠田 裕介, 澤田 良子, 大木 孝裕, 小林 寛, 平井 利英, 池上 政周, 五嶋 孝博, 田中 栄, 芳賀 信彦, 河野 博隆
    (公社)日本整形外科学会, Mar. 2015, 日本整形外科学会雑誌, 89(3) (3), S850 - S850, Japanese

  • 治療終了後から17年経過して心転移をきたしたmyxoid liposarcomaの1例
    谷 彰一郎, 大木 孝裕, 澤田 良子, 篠田 裕介, 森崎 裕, 門野 夕峰, 河野 博隆, 田中 栄
    関東整形災害外科学会, Oct. 2014, 関東整形災害外科学会雑誌, 45(5) (5), 374 - 374, Japanese

  • 自然経過で縮小傾向を示した尺骨腫瘍の1例
    大友 望, 津田 祐輔, 澤田 良子, 篠田 裕介, 門野 夕峰, 河野 博隆, 田中 栄
    関東整形災害外科学会, Jun. 2014, 関東整形災害外科学会雑誌, 45(3) (3), 193 - 193, Japanese

  • 骨転移キャンサーボード(CB)による骨転移の運動器マネージメント 整形外科の役割と潜在的要対応骨転移症例の存在
    澤田 良子, 篠田 裕介, 大熊 加恵, 稲田 修士, 金井 良晃, 岩瀬 哲, 中川 恵一, 津田 祐輔, 田中 栄, 河野 博隆
    (NPO)日本緩和医療学会, Jun. 2014, 日本緩和医療学会学術大会プログラム・抄録集, 19回, 394 - 394, Japanese

  • 骨転移手術における骨転移キャンサーボード介入の効果
    篠田 裕介, 澤田 良子, 大熊 加惠, 稲田 修士, 金井 良晃, 岩瀬 哲, 中川 恵一, 津田 祐輔, 田中 栄, 河野 博隆
    (NPO)日本緩和医療学会, Jun. 2014, 日本緩和医療学会学術大会プログラム・抄録集, 19回, 394 - 394, Japanese

  • 篠田 裕介, 澤田 良子, 津田 祐輔, 大隈 知威, 小林 寛, 池上 政周, 大木 孝裕, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2014, 日本整形外科学会雑誌, 88(6) (6), S1101 - S1101, Japanese

  • 津田 祐輔, 康永 秀生, 澤田 良子, 篠田 裕介, 大木 孝裕, 池上 政周, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2014, 日本整形外科学会雑誌, 88(6) (6), S1102 - S1102, Japanese

  • 池上 政周, 五嶋 孝博, 大木 孝裕, 橋倉 一彰, 山川 聖史, 穂積 高広, 福田 由美子, 加藤 生真, 元井 亨, 澤田 良子, 津田 祐輔, 小林 寛, 大隈 知威, 篠田 裕介, 河野 博隆, 田中 栄
    (公社)日本整形外科学会, Jun. 2014, 日本整形外科学会雑誌, 88(6) (6), S1146 - S1146, Japanese

  • 津田 祐輔, 篠田 裕介, 中川 徹, 金谷 淳志, 山田 幸央, 澤田 良子, 久米 春喜, 大木 孝裕, 池上 政周, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2014, 日本整形外科学会雑誌, 88(6) (6), S1210 - S1210, Japanese

  • 河野 博隆, 原 尚子, 飯田 拓也, 三原 誠, 成島 三長, 篠田 裕介, 津田 祐輔, 澤田 良子, 大隈 知威, 小林 寛, 五嶋 孝博, 池上 政周, 大木 孝裕, 田中 栄, 光嶋 勲
    (公社)日本整形外科学会, Jun. 2014, 日本整形外科学会雑誌, 88(6) (6), S1240 - S1240, Japanese

  • 河野 博隆, 篠田 裕介, 津田 祐輔, 澤田 良子, 大隈 知威, 小林 寛, 五嶋 孝博, 池上 政周, 大木 孝裕, 田中 栄
    (公社)日本整形外科学会, Jun. 2014, 日本整形外科学会雑誌, 88(6) (6), S1246 - S1246, Japanese

  • 篠田 裕介, 久米 春喜, 澤田 良子, 津田 祐輔, 大隈 知威, 小林 寛, 中川 徹, 山田 幸央, 池上 政周, 大木 孝裕, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2014, 日本整形外科学会雑誌, 88(6) (6), S1262 - S1262, Japanese

  • 尿路上皮癌における骨転移と骨関連事象
    津田 祐輔, 篠田 裕介, 中川 徹, 金谷 淳志, 川合 剛人, 山田 幸央, 澤田 良子, 久米 春喜, 河野 博隆, 本間 之夫, 田中 栄
    (一社)日本癌治療学会, Jun. 2014, 日本癌治療学会誌, 49(3) (3), 880 - 880, Japanese

  • 骨転移キャンサーボードの介入により骨転移患者のQOLが改善する
    篠田 裕介, 澤田 良子, 金井 良晃, 中川 恵一, 岩瀬 哲, 津田 祐輔, 五嶋 孝博, 田中 栄, 河野 博隆
    (一社)日本癌治療学会, Jun. 2014, 日本癌治療学会誌, 49(3) (3), 886 - 886, Japanese

  • 篠田 裕介, 澤田 良子, 西坂 智佳, 正田 奈緒子, 緒方 直史, 芳賀 信彦, 津田 祐輔, 田中 栄, 河野 博隆
    (公社)日本リハビリテーション医学会, May 2014, The Japanese Journal of Rehabilitation Medicine, 51(Suppl.) (Suppl.), S258 - S258, Japanese

  • 西坂 智佳, 緒方 直史, 中原 康雄, 澤田 良子, 篠田 裕介, 芳賀 信彦
    (公社)日本リハビリテーション医学会, May 2014, The Japanese Journal of Rehabilitation Medicine, 51(Suppl.) (Suppl.), S258 - S258, Japanese

  • 澤田 良子, 篠田 裕介, 津田 祐輔, 池上 政周, 大木 孝裕, 五嶋 孝博, 金井 良晃, 岩瀬 哲, 中川 恵一, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Mar. 2014, 日本整形外科学会雑誌, 88(2) (2), S311 - S311, Japanese

  • 津田 祐輔, 河野 博隆, 篠田 裕介, 澤田 良子, 小林 寛, 大隈 知威, 大木 孝裕, 池上 政周, 五嶋 孝博, 田中 栄
    (公社)日本整形外科学会, Mar. 2014, 日本整形外科学会雑誌, 88(3) (3), S665 - S665, Japanese

  • 池上 政周, 五嶋 孝博, 大木 孝弘, 橋倉 一彰, 福田 由美子, 加藤 生真, 元井 亨, 澤田 良子, 津田 祐輔, 篠田 裕介, 河野 博隆
    (公社)日本整形外科学会, Mar. 2014, 日本整形外科学会雑誌, 88(3) (3), S666 - S666, Japanese

  • 骨転移診療における緩和医療とリハビリテーション医療の融合 運動器マネージメントがもたらす新しい緩和ケアの世界
    篠田 裕介, 岩瀬 哲, 中川 恵一, 金井 良晃, 澤田 良子, 津田 祐輔, 五嶋 孝博, 田中 栄, 河野 博隆
    (一社)日本癌治療学会, Sep. 2013, 日本癌治療学会誌, 48(3) (3), 603 - 603, Japanese

  • 篠田 裕介, 大橋 暁, 津田 祐輔, 澤田 良子, 河野 博隆, 田中 栄
    東日本整形災害外科学会, Aug. 2013, 東日本整形災害外科学会雑誌, 25(3) (3), 347 - 347, Japanese

  • 平林 健一, 津田 祐輔, 篠田 裕介, 澤田 良子, 河野 博隆, 田中 栄
    東日本整形災害外科学会, Aug. 2013, 東日本整形災害外科学会雑誌, 25(3) (3), 386 - 386, Japanese

  • 足根骨に発生したchondroblastomaの2例
    後藤 和海, 澤田 良子, 篠田 裕介, 安井 哲郎, 伊藤 英也, 河野 博隆, 田中 栄
    関東整形災害外科学会, Jun. 2013, 関東整形災害外科学会雑誌, 44(3) (3), 112 - 112, Japanese

  • 河野 博隆, 五嶋 孝博, 篠田 裕介, 津田 祐輔, 池上 政周, 大隈 知威, 小林 寛, 小倉 浩一, 澤田 良子, 秋山 達, 平田 真, 今西 淳悟, 山本 愛一郎, 田中 栄
    (公社)日本整形外科学会, Jun. 2013, 日本整形外科学会雑誌, 87(6) (6), S1143 - S1143, Japanese

  • 津田 祐輔, 五嶋 孝博, 池上 政周, 佐藤 敏秀, 田中 伸弥, 山川 聖史, 穂積 高弘, 福田 由美子, 加藤 生真, 元井 亨, 北原 康行, 高木 康伸, 篠田 裕介, 澤田 良子, 河野 博隆, 田中 栄
    (公社)日本整形外科学会, Jun. 2013, 日本整形外科学会雑誌, 87(6) (6), S1151 - S1151, Japanese

  • 篠田 裕介, 澤田 良子, 大隈 知威, 小林 寛, 小倉 浩一, 津田 祐輔, 池上 政周, 大木 孝裕, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2013, 日本整形外科学会雑誌, 87(6) (6), S1161 - S1161, Japanese

  • 津田 祐輔, 五嶋 孝博, 池上 政周, 佐藤 敏秀, 田中 伸弥, 山川 聖史, 穂積 高弘, 福田 由美子, 加藤 生真, 元井 亨, 篠田 裕介, 大隈 知威, 澤田 良子, 河野 博隆, 田中 栄
    (公社)日本整形外科学会, Jun. 2013, 日本整形外科学会雑誌, 87(6) (6), S1180 - S1180, Japanese

  • 池上 政周, 五嶋 孝博, 津田 祐輔, 山田 直樹, 佐藤 敏秀, 田中 伸弥, 山川 聖史, 穂積 高弘, 澤田 良子, 小林 寛, 大隈 知威, 篠田 裕介, 河野 博隆, 田中 栄
    (公社)日本整形外科学会, Jun. 2013, 日本整形外科学会雑誌, 87(6) (6), S1201 - S1201, Japanese

  • 篠田 裕介, 澤田 良子, 前田 大地, 大隈 知威, 小林 寛, 小倉 浩一, 津田 祐輔, 池上 政周, 大木 孝裕, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2013, 日本整形外科学会雑誌, 87(6) (6), S1201 - S1201, Japanese

  • 池上 政周, 五嶋 孝博, 津田 祐輔, 山田 直樹, 佐藤 敏秀, 田中 伸弥, 山川 聖史, 穂積 高弘, 福田 由美子, 加藤 生真, 元井 亨, 東川 晶郎, 澤田 良子, 篠田 裕介, 河野 博隆, 田中 栄
    (公社)日本整形外科学会, Jun. 2013, 日本整形外科学会雑誌, 87(6) (6), S1210 - S1210, Japanese

  • 澤田 良子, 篠田 裕介, 大隈 知威, 小林 寛, 小倉 浩一, 津田 祐輔, 池上 政周, 大木 孝裕, 五嶋 孝博, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Jun. 2013, 日本整形外科学会雑誌, 87(6) (6), S1221 - S1221, Japanese

  • 山田 直樹, 津田 祐輔, 五嶋 孝博, 池上 政周, 佐藤 敏秀, 田中 伸弥, 山川 聖史, 穂積 高弘, 福田 由美子, 加藤 生真, 元井 亨, 篠田 裕介, 大隈 知威, 澤田 良子, 河野 博隆, 田中 栄
    (公社)日本整形外科学会, Jun. 2013, 日本整形外科学会雑誌, 87(6) (6), S1227 - S1227, Japanese

  • 篠田 裕介, 大橋 暁, 金子 雅子, 林 直人, 澤田 良子, 小倉 浩一, 五嶋 孝博, 津田 祐輔, 池上 政周, 田中 栄, 河野 博隆
    (公社)日本整形外科学会, Mar. 2013, 日本整形外科学会雑誌, 87(2) (2), S108 - S108, Japanese

  • 上原 浩介, 森崎 裕, 坂井 邦臣, 澤田 良子, 篠田 裕介, 河野 博隆, 田中 栄
    (公社)日本整形外科学会, Mar. 2013, 日本整形外科学会雑誌, 87(3) (3), S725 - S725, Japanese

  • 小児大腿皮下に発生したangiomatoid fibrous histiocytomaの1例
    鹿毛 智文, 澤田 良子, 篠田 裕介, 武冨 修治, 筑田 博隆, 河野 博隆, 田中 栄
    関東整形災害外科学会, Oct. 2012, 関東整形災害外科学会雑誌, 43(5) (5), 422 - 423, Japanese

  • 河野 博隆, 篠田 裕介, 澤田 良子, 五嶋 孝博, 津田 祐輔
    東日本整形災害外科学会, Aug. 2012, 東日本整形災害外科学会雑誌, 24(3) (3), 434 - 434, Japanese

  • 超高齢者骨折に対するイリザロフ創外固定の1例
    森島 拓, 岡崎 裕司, 吉富 洋樹, 三宅 良子, 西本 雄飛, 村島 一平, 兵頭 晃, 夏山 元伸
    関東整形災害外科学会, Jun. 2012, 関東整形災害外科学会雑誌, 43(3) (3), 225 - 225, Japanese

  • 大腿骨遠位骨端線損傷後の成長障害に対し鏡視下Langenskioeld法を行った1例
    三宅 良子, 岡崎 裕司, 吉冨 洋樹, 西本 雄飛, 村島 一平, 小林 康一, 兵頭 晃, 夏山 元伸
    関東整形災害外科学会, Jun. 2012, 関東整形災害外科学会雑誌, 43(3) (3), 227 - 227, Japanese

  • 脊柱管内腫瘍と鑑別が困難であった脱出椎間板ヘルニアの3例
    関屋 辰洋, 夏山 元伸, 安部 博昭, 東川 晶郎, 小林 洋介, 三宅 良子, 岡崎 裕司
    関東整形災害外科学会, Feb. 2012, 関東整形災害外科学会雑誌, 43(1) (1), 77 - 77, Japanese

  • 脊柱管内腫瘍と鑑別が困難であった脱出椎間板ヘルニアの3例
    関屋 辰洋, 渡邉 健一, 夏山 元伸, 安部 博昭, 東川 晶郎, 河野 龍太, 小林 洋介, 三宅 良子, 吉冨 洋樹, 岡崎 裕司
    関東整形災害外科学会, Sep. 2011, 関東整形災害外科学会雑誌, 42(臨増号外) (臨増号外), 178 - 178, Japanese

  • 関屋 辰洋, 渡邉 健一, 夏山 元伸, 安部 博昭, 東川 晶郎, 河野 龍太, 小林 洋介, 三宅 良子, 吉冨 洋樹, 岡崎 裕司
    東日本整形災害外科学会, Aug. 2011, 東日本整形災害外科学会雑誌, 23(3) (3), 446 - 446, Japanese

  • 肝細胞癌大腿骨転移に対する観血的内固定術にラジオ波焼灼術を補助療法として用いた1例
    三宅 良子, 大隈 知威, 小林 寛, 篠田 裕介, 河野 博隆, 中村 耕三
    関東整形災害外科学会, Aug. 2010, 関東整形災害外科学会雑誌, 41(4) (4), 238 - 238, Japanese

  • 三宅 良子, 儘田 敏且, 杉田 守礼, 北見 聡史, 横倉 聡, 飯島 卓夫
    東日本整形災害外科学会, Aug. 2010, 東日本整形災害外科学会雑誌, 22(3) (3), 515 - 515, Japanese

  • 肝細胞癌大腿骨転移に対する観血的内固定術にラジオ波焼灼術を補助療法として用いた1例
    三宅 良子, 大隈 知威, 小林 寛, 篠田 裕介, 秋山 達, 河野 博隆, 中村 耕三
    関東整形災害外科学会, Mar. 2010, 関東整形災害外科学会雑誌, 41(臨増号外) (臨増号外), 90 - 90, Japanese

  • 混合型IPMNの1切除例
    河口 義邦, 酒向 晃弘, 三宅 良子, 高橋 悠, 室野 浩司, 片山 裕子, 西山 綾子, 青木 茂雄, 山口 龍志郎, 清松 知充, 伊藤 吾子, 上田 和光, 奥村 稔
    (一社)茨城県医師会, Mar. 2009, 茨城県臨床医学雑誌, (44) (44), 44 - 44, Japanese

  • 消化管出血をきたしたBlue Rubber Bleb Nevus症候群の一例
    三宅 良子, 金沢 孝満, 吉川 善子, 志田 大, 須並 英二, 北山 丈二, 名川 弘一
    日本臨床外科学会, Feb. 2009, 日本臨床外科学会雑誌, 70(2) (2), 630 - 630, Japanese

  • 再発・遷延性の経過を呈したFisher症候群の1例
    田宮 寛之, 河内 覚, 伊藤 桜子, 菅沼 大, 三宅 良子, 藤田 恒夫, 平塚 健太郎, 戸島 均
    日本内科学会-関東地方会, Oct. 2008, 日本内科学会関東地方会, 557回, 34 - 34, Japanese

  • 混合型IPMNの1切除例
    河口 義邦, 酒向 晃弘, 三宅 良子, 高橋 悠, 室野 浩司, 片山 裕子, 西山 綾子, 青木 茂雄, 山口 龍志郎, 清松 知充, 伊藤 吾子, 上田 和光, 奥村 稔
    日本臨床外科学会, Mar. 2008, 日本臨床外科学会雑誌, 69(3) (3), 722 - 722, Japanese

■ Research Themes
  • Effects of an antioxidant flavonoid on muscle atrophy associated with cachexia in pediatric osteosarcoma
    深瀬 直政, 澤田 良子, 原 仁美, 藤原 周一, 秋末 敏宏
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2024 - 31 Mar. 2027

  • 骨転移患者の就労阻害因子の同定と至適支援方法の確立
    澤田 良子
    日本学術振興会, 科学研究費助成事業, 若手研究, 神戸大学, 01 Apr. 2023 - 31 Mar. 2026

  • サルコペニアの骨格筋に対する経皮的炭酸ガス投与法の効果について
    原 仁美, 竹森 俊幸, 河本 旭哉, 藤原 周一, 秋末 敏宏, 深瀬 直政, 澤田 良子
    日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 01 Apr. 2022 - 31 Mar. 2025
    サルコペニアの成因や病態については明らかにされていない部分も多く、基礎研究が進行中であるが、臨床的には診断ガイドラインも作成されており、予防や治療法の確立が望まる。現在のところ、有効な治療法としてエビデンスが示されているのは運動療法だけであり、薬物治療や栄養療法についてのエビデンスは不十分である。サルコペニアはロコモティブシンドローム、フレイルと並んで高齢者の運動機能、身体機能の低下として問題となるが、高齢者では、運動器の慢性変性疾患による疼痛やしびれなどの自覚症状を有することが多く、さらに基礎疾患による運動制限や認知機能や気力の低下もあるため、運動療法を習慣化させることが困難である。経皮的炭酸ガス療法は運動能力が低下した状態においても施術が可能で低侵襲な新規治療法として、我々は既に骨折や悪性軟部腫瘍に対する臨床研究を行っている。有酸素運動と同様の効果が得られる本治療法が、サルコペニアに対して有効であることが示されれば、臨床応用ができ、高齢社会において大きく貢献することが可能であると考える。 そのためにはまず、自然発症高血圧ラット（SHR）に高脂肪高炭水化物食を負荷したモデル（サルコペニアラット）を使用し、経皮的炭酸ガス療法を行う。経皮的炭酸ガス治療群とコントロール群で体組成の評価を行い、摘出した骨格筋組織で病理組織学的、分子生物学的に筋量や筋サテライト細胞数の評価、筋タンパクの合成と分解に関連する因子についての評価を行う予定である。

  • Development of new treatment strategies for osteosarcoma using induced osteosarcoma stem cells
    河本 旭哉, 青井 貴之, 竹森 俊幸, 森下 雅之, 深瀬 直政, 原 仁美, 澤田 良子, 秋末 敏宏
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2021 - 31 Mar. 2024
    本研究の目的は，我々が初めて作製に成功した人工骨肉腫幹細胞を用いて，骨肉腫の腫瘍発生・増生，再発・転移，治療抵抗性に関わる因子を解明することである．さらに，得られた結果を用いて臨床的に応用可能な治療標的を同定し，新規治療開発を行うことを目指す． これまでに，ヒト骨肉腫由来細胞株MG63にレトロウイルスベクターを用いてOCT3/4，KLF4，SOX2の3遺伝子を導入して作製した人工骨肉腫幹細胞MG-OKSと，同様の方法でGFPを導入して作製したコントロール細胞MG-GFPを用いて，各細胞における幹細胞関連マーカー，細胞増殖能，細胞遊走能，スフェア形成能等幹細胞特性の検討を行ったところ，MG-OKSでは幹細胞関連マーカーの発現上昇，細胞増殖能低下，細胞遊走能上昇，スフェア形成能上昇がみられ，幹細胞特性を有していることを明らかとした．さらに人工骨肉腫細胞MG-OKS，コントロール細胞MG-GFPおよび親細胞株MG-63の網羅的遺伝子解析をMicroarrayで行ったところ，MG-OKSにおいてMG-GFPおよびMG-63よりも10倍以上発現上昇をみとめた遺伝子が200個以上検出された．同遺伝子群の機能解析をGene ontologyを用いて行ったところ，悪性腫瘍との関連が報告されている遺伝子群の発現上昇が確認された．これら遺伝子群からSPRR1A遺伝子に着目し，治療標的あるいは腫瘍マーカーとして応用可能かについて現在様々な検討を行っている．

TOP